fluorouracil

Overview
Prescribing Info
Drug Label Annotations
Clinical Annotations
Variant Annotations
Literature
Pathways
Related To
Links
Navigate to...
Show section selector dropdown

Literature

The publications shown below are associated with this chemical in PharmGKB based on (1) literature annotations, (2) variant annotations, (3) VIP summaries, or (4) pathways.

    363 items
    Literature
    Severe fluoropyrimidine toxicity in older adults with cancer with DPYD wild type.
    Fundamental & clinical pharmacology. 2025. Brokaar Edwin, Knikman Jonathan, Visser Loes, van den Bos Frederiek, Henricks Linda, Lunenburg Carin, de Man Femke, Gelderblom Hans, Schellens Jan, Mathijssen Ron, Guchelaar Henk-Jan, Portielje Johanneke, Cats Annemieke, Postmus Wout and de Glas Nienke.
    PGx Paper Type: Methods
    Literature
    Feasibility and population exposure of 5-fluorouracil using therapeutic drug monitoring (PREDICT-5FU): A multicentre clinical trial.
    British journal of clinical pharmacology. 2025. Glewis Sarah, Michael Michael, Gurney Howard, Olver Ian, Zdenkowski Nicholas, Ackland Stephen, Kukard Craig, Jayawardana Madawa, Silva S Sandun M, Alexander Marliese, Tie Jeanne, Galettis Peter and Martin Jennifer H.
    PGx Paper Type: Implementation
    Literature
    Thymine as potential biomarker to predict 5-FU systemic exposure in patients with gastro-intestinal cancer: a prospective pharmacokinetic study (FUUT-trial).
    Cancer chemotherapy and pharmacology. 2025. Hanrath Maarten A, Banken Evi, van den Wildenberg Sebastian A H, van de Kerkhof Daan, Moes Dirk Jan A R, Boisdron-Celle Michele, van den Bosch Bianca J C, Bax Ramon, Bet Pierre M, Maring Jan Gerard, Creemers Geert-Jan M, van Hellemond Irene E G and Deenen Maarten J.
    PGx Paper Type: Implementation, Methods
    Literature
    A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice.
    Clinical pharmacology and therapeutics. 2025. Ho Teresa T, Smith D Max, Aquilante Christina L, Cicali Emily J, El Rouby Nihal, Hertz Daniel L, Imanirad Iman, Patel Jai N, Scott Stuart A, Swain Sandra M, Tuteja Sony, Hicks J Kevin and Pharmacogenomics Global Research Network Publication Committee.
    PGx Paper Type: Implementation
    Literature
    Pharmacogenetics: Opportunities for the All of Us Research Program and Other Large Data Sets to Advance the Field.
    Annual review of pharmacology and toxicology. 2025. Empey Philip E, Karnes Jason H and Johnson Julie A.
    PGx Paper Type: Implementation, Review
    Literature
    Relationship between neutropenia caused by nanoliposomal irinotecan/fluorouracil/leucovorin and treatment outcomes in the NAPOLEON-2 study (NN-2301).
    Scientific reports. 2025. Araki Tomonori, Sonoda Yuki, Shimokawa Mototsugu, Otsuka Taiga, Hayashi Kohei, Honda Takuya, Nakao Kazuhiko, Shibuki Taro, Nakazawa Junichi, Arima Shiho, Miwa Keisuke, Okabe Yoshinobu, Koga Futa, Ueda Yujiro, Kubotsu Yoshihito, Shimokawa Hozumi, Takeshita Shigeyuki, Komori Azusa, Nishikawa Kazuo, Otsu Satoshi, Hosokawa Ayumu, Oda Hisanobu, Sakai Tatsunori, Arita Shuji, Kawahira Machiko, Taguchi Hiroki, Tsuneyoshi Kengo, Kawaguchi Yasunori, Fujita Toshihiro, Sakae Takahiro, Shirakawa Tsuyoshi, Mizuta Toshihiko and Mitsugi Kenji.
    Literature
    Clinical Benefits and Utility of Pretherapeutic DPYD and UGT1A1 Testing in Gastrointestinal Cancer: A Secondary Analysis of the PREPARE Randomized Clinical Trial.
    JAMA network open. 2024. Roncato Rossana, Bignucolo Alessia, Peruzzi Elena, Montico Marcella, De Mattia Elena, Foltran Luisa, Guardascione Michela, D'Andrea Mario, Favaretto Adolfo, Puglisi Fabio, Swen Jesse Joachim, Guchelaar Henk-Jan, Toffoli Giuseppe and Cecchin Erika.
    PGx Paper Type: Implementation, Pharmacoeconomics
    Literature
    Give Patients the Choice to Test for DPD Deficiency Before Fluoropyrimidine Chemotherapy.
    JCO oncology practice. 2024. Surprenant Ken, Murray Lindsay, Merritt Karen, Hopkins Maria and McIntyre Joanne.
    PGx Paper Type: Implementation, Commentary
    Literature
    Pharmacogenetic-guided dosing for fluoropyrimidine (DPYD) and irinotecan (UGT1A1*28) chemotherapies for patients with cancer (PACIFIC-PGx): A multicenter clinical trial.
    Clinical and translational science. 2024. Glewis Sarah, Lingaratnam Senthil, Lee Benjamin, Campbell Ian, IJzerman Maarten, Fagery Mussab, Harris Sam, Georgiou Chloe, Underhill Craig, Warren Mark, Campbell Robert, Jayawardana Madawa, Silva S Sandun M, Martin Jennifer H, Tie Jeanne, Alexander Marliese and Michael Michael.
    PGx Paper Type: Implementation, Population Frequency
    Literature
    Pharmacogenomics: DPYD and Prevention of Toxicity.
    Clinical oncology (Royal College of Radiologists (Great Britain)). 2024. Keen J, McDermott J H, Aguilar-Martinez E and Newman W G.
    PGx Paper Type: Implementation, Review
    Literature
    Plasma clearance of 5-fluorouracil is more influenced by variations in glomerular filtration rate than by uracil concentration.
    Cancer chemotherapy and pharmacology. 2024. Matheux Alice, Collas Laurine, Grisard Maelle, Goulaieff Léa, Ghiringhelli François, Bengrine-Lefevre Leïla, Vincent Julie, Goirand Francoise, Royer Bernard and Schmitt Antonin.
    PGx Paper Type: Methods
    Literature
    DPYD genotype-guided dose personalisation for fluoropyrimidine-based chemotherapy prescribing in solid organ cancer patients in Australia: GeneScreen 5-FU study protocol.
    BMC cancer. 2024. White Cassandra, Wardill Hannah, Paul Christine, Price Timothy, Karapetis Christos, Nalder Mark, Burge Matthew E, Thomas Ann, Oldmeadow Chris, Barker Daniel, Edney Laura C, Coller Janet, Bowen Joanne, Ostroff Cheri, Cheek Bruce, Carlson Mel, Rankmore Trumaine, Nagrial Adnan, Clarke Stephen, Chantrill Lorraine, Ackland Stephen and Scott Rodney J.
    PGx Paper Type: Implementation
    Literature
    Understanding the Biology and Testing Techniques for Pharmacogenomics in Oncology: A Practical Guide for the Clinician.
    JCO oncology practice. 2024. Steuerwald Nury M, Morris Sarah, Nguyen D Grace and Patel Jai N.
    PGx Paper Type: Implementation, Review
    Literature
    Association Between Changes in Plasma Capecitabine Concentrations and Adverse Events in the Treatment of Colorectal Cancer.
    Cureus. 2024. Hashimoto Yasuhiro, Yoshida Yoichiro, Yamada Teppei, Yoshimatsu Gumpei, Yoshimura Fumihiro and Hasegawa Suguru.
    PGx Paper Type: Methods
    Literature
    DPYD Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, American College of Medical Genetics and Genomics, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, Pharmacogenomics Knowledgebase, and Pharmacogene Variation Consortium.
    The Journal of molecular diagnostics : JMD. 2024. Pratt Victoria M, Cavallari Larisa H, Fulmer Makenzie L, Gaedigk Andrea, Hachad Houda, Ji Yuan, Kalman Lisa V, Ly Reynold C, Moyer Ann M, Scott Stuart A, Turner Amy J, van Schaik Ron H N, Whirl-Carrillo Michelle and Weck Karen E.
    PGx Paper Type: Implementation
    Literature
    Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2024. Leong Ivone U S, Cabrera Claudia P, Cipriani Valentina, Ross Paul J, Turner Richard M, Stuckey Alex, Sanghvi Sonali, Pasko Dorota, Moutsianas Loukas, Odhams Christopher A, Elgar Greg S, Chan Georgia, Giess Adam, Walker Susan, Foulger Rebecca E, Williams Eleanor M, Daugherty Louise C, Rueda-Martin Antonio, Rhodes Daniel J, Niblock Olivia, Pickard Alexandra, Marks Lauren, Leigh Sarah E A, Welland Matthew J, Bleda Marta, Snow Catherine, Deans Zandra, Murugaesu Nirupa, Scott Richard H, Barnes Michael R, Brown Matthew A, Rendon Augusto, Hill Sue, Sosinsky Alona, Caulfield Mark J and McDonagh Ellen M.
    PGx Paper Type: Implementation, Population Frequency
    Literature
    Review of the fluoropyrimidine antidote uridine triacetate.
    British journal of clinical pharmacology. 2024. Thompson Jack T, Wood David M and Dargan Paul I.
    PGx Paper Type: Review
    Literature
    DPD deficiency in an Irish oncology centre: Prevalence and clinical implications.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2024. Kieran Ruth, Mitchell Taylor, Fazari Afrah Al, Chinoy Aleena, Moloney Carolyn and McCaffrey John.
    PGx Paper Type: Implementation, Population Frequency
    Literature
    Evaluation of chemotherapy toxicities in patients receiving treatment for gastrointestinal cancers and therapeutic monitoring of 5-fluorouracil as a clinical support tool.
    Fundamental & clinical pharmacology. 2024. de Baco Lucas Silva, da Silva Laura Cé, Antunes Luis Carlos Moreira, Antunes Marina Venzon, Linden Rafael, Moreira Mauber Eduardo Schultz, Radins Ricardo Bolsson, Maranhão Sarayane Araújo Brandão, da Silva Barbosa Sylvio Elvis, Volpato Lucimara, Stefanon Lauren Razzera and Brucker Natália.
    PGx Paper Type: Methods
    Literature
    Management of patients with reduced dihydropyrimidine dehydrogenase activity receiving combined 5-fluoruracil-/capecitabine-based chemoradiotherapy.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]. 2024. Hoffmann E, Toepell A, Peter A, Böke S, De-Colle C, Steinle M, Niyazi M and Gani C.
    PGx Paper Type: Implementation
    Literature
    DPYD genetic polymorphisms in non-European patients with severe fluoropyrimidine-related toxicity: a systematic review.
    British journal of cancer. 2024. Chan Tsun Ho, Zhang J Eunice and Pirmohamed Munir.
    PGx Paper Type: Population Frequency, Review
    Literature
    Diversity of oncopharmacogenetic profile within Spanish population.
    Pharmacogenetics and genomics. 2024. Ferrer Bolufer Irene, Galiana Vallés Ximo, Izquierdo Álvarez Silvia, Serrano Mira Ana, Guzmán Luján Carola, Safont Aguilera María José, González Tarancón Ricardo, Bolaños Naranjo Matilde, Carrasco Salas Pilar, Santamaría González María and Rodríguez-López Raquel.
    PGx Paper Type: Implementation, Population Frequency
    Literature
    Personalized Chronomodulated 5-Fluorouracil Treatment: A Physiologically-Based Pharmacokinetic Precision Dosing Approach for Optimizing Cancer Therapy.
    Clinical pharmacology and therapeutics. 2024. Marok Fatima Zahra, Wojtyniak Jan-Georg, Selzer Dominik, Dallmann Robert, Swen Jesse J, Guchelaar Henk-Jan, Schwab Matthias and Lehr Thorsten.
    PGx Paper Type: Methods
    Literature
    Pharmacogenetic Testing or Therapeutic Drug Monitoring: A Quantitative Framework.
    Clinical pharmacokinetics. 2024. Centanni Maddalena, Reijnhout Niels, Thijs Abel, Karlsson Mats O and Friberg Lena E.
    PGx Paper Type: Implementation, Methods
    Literature
    Real-World Impact of an In-House Dihydropyrimidine Dehydrogenase ( DPYD) Genotype Test on Fluoropyrimidine Dosing, Toxicities, and Hospitalizations at a Multisite Cancer Center.
    JCO precision oncology. 2024. Nguyen D Grace, Morris Sarah A, Hamilton Alicia, Kwange Simeon O, Steuerwald Nury, Symanowski James, Moore Donald C, Hanson Sarah, Mroz Kaitlyn, Lopes Karine E, Larck Chris, Musselwhite Laura, Kadakia Kunal C, Koya Brinda, Chai Seungjean, Osei-Boateng Kwabena, Kalapurakal Sini, Swift Kristen, Hwang Jimmy and Patel Jai N.
    PGx Paper Type: Implementation
    Literature
    Impact of hemolysis on uracilemia in the context of dihydropyrimidine dehydrogenase deficiency testing.
    Clinical chemistry and laboratory medicine. 2024. Loison Gaspard, Bouges Le Royer Hélène, Marsili Sabrina, Brice Aurélie, Vintejoux Julien, Yakoubi Malika, Sirgue Hélène, Chatelut Etienne, Etienne-Grimaldi Marie-Christine, Thomas Fabienne and on behalf of the GPCO-UNICANCER group.
    PGx Paper Type: Methods
    Literature
    DPYD genotyping panels: Impact of population diversity.
    Clinical and translational science. 2024. Suarez-Kurtz Guilherme.
    PGx Paper Type: Implementation, Population Frequency, Commentary
    Literature
    Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase ( DPYD).
    eLife. 2024. Zhang Ting, Ambrodji Alisa, Huang Huixing, Bouchonville Kelly J, Etheridge Amy S, Schmidt Remington E, Bembenek Brianna M, Temesgen Zoey B, Wang Zhiquan, Innocenti Federico, Stroka Deborah, Diasio Robert B, Largiadèr Carlo R and Offer Steven M.
    PGx Paper Type: Population Frequency, Drug-Gene Interaction for Pathway
    Literature
    Overcoming Barriers to Discovery and Implementation of Equitable Pharmacogenomic Testing in Oncology.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2024. Shriver Sharon P, Adams Devon, McKelvey Brittany Avin, McCune Jeannine S, Miles Dale, Pratt Victoria M, Ashcraft Kristine, McLeod Howard L, Williams Hannah and Fleury Mark E.
    PGx Paper Type: Implementation, Population Frequency, Review, Pharmacoeconomics, Uses PharmGKB
    Literature
    Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis.
    British journal of cancer. 2024. Le Teuff Gwénaël, Cozic Nathalie, Boyer Jean-Christophe, Boige Valérie, Diasio Robert B, Taieb Julien, Meulendijks Didier, Palles Claire, Schwab Matthias, Deenen Maarten, Largiadèr Carlo R, Marinaki Anthony, Jennings Barbara A, Wettergren Yvonne, Di Paolo Antonello, Gross Eva, Budai Barna, Ackland Stephen P, van Kuilenburg André B P, McLeod Howard L, Milano Gérard, Thomas Fabienne, Loriot Marie-Anne, Kerr David, Schellens Jan H M, Laurent-Puig Pierre, Shi Qian, Pignon Jean-Pierre, Etienne-Grimaldi Marie-Christine and FUSAFE collaborative group.
    PGx Paper Type: Implementation, Methods
    Literature
    Drugs@FDA: Drug Product FLUOROURACIL (FLUOROURACIL), Eugia US LLC - ANDA202669/SUPPL-9, 03/21/2024
    2024.
    Literature
    Drugs@FDA: Drug Product Fluorouracil (Fluorouracil), BluePoint Laboratories - ANDA210124/SUPPL-9, 03/21/2024
    2024.
    Literature
    Risk of Toxicity From Topical 5-Fluorouracil Treatment in Patients Carrying DPYD Variant Alleles.
    Clinical pharmacology and therapeutics. 2024. Granados Javier, Pasternak Amy L, Henry N Lynn, Sahai Vaibhav and Hertz Daniel L.
    PGx Paper Type: Implementation
    Literature
    Assessing the utility of measurement methods applied in economic evaluations of pharmacogenomics applications.
    Pharmacogenomics. 2024. Fragoulakis Vasileios, Koufaki Margarita-Ioanna, Tzerefou Korina, Koufou Konstantinos, Patrinos George P and Mitropoulou Christina.
    PGx Paper Type: Implementation, Pharmacoeconomics
    Literature
    Clinical Implementation of Rare and Novel DPYD Variants for Personalizing Fluoropyrimidine Treatment: Challenges and Opportunities.
    International journal of biological sciences. 2024. De Mattia Elena, Milan Noemi, Assaraf Yehuda G, Toffoli Giuseppe and Cecchin Erika.
    PGx Paper Type: Implementation, Review
    Literature
    5-Fluorouracil Neurotoxicity in a Patient With Normal Dihydropyrimidine Dehydrogenase Activity.
    Cureus. 2023. Natarajan Ulaganathan, Onyechi Afoma and Ohemeng-Dapaah Jessica.
    PGx Paper Type: Implementation
    Literature
    A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancer.
    Cancer chemotherapy and pharmacology. 2023. Shibata Yukitaka, Matsumoto Natsumi, Murase Remi, Kubota Yutaro, Ishida Hiroo, Shimada Ken and Fujita Ken-Ichi.
    Literature
    Response to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy.
    Clinical pharmacology and therapeutics. 2023. Hertz Daniel L, Smith D Max, Scott Stuart A, Patel Jai N and Hicks J Kevin.
    PGx Paper Type: Implementation, Review
    Literature
    DPYD and TYMS polymorphisms as predictors of 5 fluorouracil toxicity in colorectal cancer patients.
    Journal of chemotherapy (Florence, Italy). 2023. Khalij Yassine, Belaid Imtinen, Chouchane Sana, Amor Dorra, Omezzine Asma, Ben Rejeb Nabila, Ben Ahmed Slim and Bouslama Ali.
    Literature
    The Role of Gender Pharmacogenetics in the Personalization of Drug Treatment.
    The Journal of pharmacology and experimental therapeutics. 2023. Cecchin Erika, Posocco Bianca, Mezzalira Silvia, Appetecchia Marialuisa and Toffoli Giuseppe.
    PGx Paper Type: Review, Uses PharmGKB
    Literature
    Prescription medications with actionable pharmacogenomic recommendations in Veterans Health Administration patients.
    Pharmacogenomics. 2023. Maghari Saba, Gallo Tyler, Rivas Salvador, German Alexander, Nguyen Le Minh Q, Abbaszadegan Hamed, Zubriski Mark A, Heise Craig W and Landas Noel D.
    PGx Paper Type: Implementation
    Literature
    DPYD Testing: Time to Put Patient Safety First.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023. Baker Sharyn D, Bates Susan E, Brooks Gabriel A, Dahut William L, Diasio Robert B, El-Deiry Wafik S, Evans William E, Figg William D, Hertz Dan L, Hicks J Kevin, Kamath Suneel, Kasi Pashtoon Murtaza, Knepper Todd C, McLeod Howard L, O'Donnell Peter H, Relling Mary V, Rudek Michelle A, Sissung Tristan M, Smith D Max, Sparreboom Alex, Swain Sandra M and Walko Christine M.
    PGx Paper Type: Implementation, Commentary
    Literature
    Clinical pharmacogenomics implementation in Thailand: a dream come true.
    Pharmacogenomics. 2023. Sukasem Chonlaphat, Biswas Mohitosh, Lungchukiet Palita and Sangtian Montinee.
    PGx Paper Type: Implementation, Editorial
    Literature
    Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre.
    BMC cancer. 2023. Lau David K, Fong Caroline, Arouri Faten, Cortez Lillian, Katifi Hannah, Gonzalez-Exposito Reyes, Razzaq Muhammad Bilal, Li Su, Macklin-Doherty Aislinn, Hernandez Monica Arenas, Hubank Michael, Fribbens Charlotte, Watkins David, Rao Sheela, Chau Ian, Cunningham David and Starling Naureen.
    PGx Paper Type: Implementation
    Literature
    Pharmacogenetics and Adverse Events in the Use of Fluoropyrimidine in a Cohort of Cancer Patients on Standard of Care Treatment in Zimbabwe.
    Journal of personalized medicine. 2023. Afolabi Boluwatife Lawrence, Mazhindu Tinashe, Zedias Chikwambi, Borok Margaret, Ndlovu Ntokozo, Masimirembwa Collen and On Behalf Of Consortium For Genomics And Therapeutics In Africa Cgta.
    PGx Paper Type: Implementation, Population Frequency
    Literature
    A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.
    Lancet (London, England). 2023. Swen Jesse J, van der Wouden Cathelijne H, Manson Lisanne En, Abdullah-Koolmees Heshu, Blagec Kathrin, Blagus Tanja, Böhringer Stefan, Cambon-Thomsen Anne, Cecchin Erika, Cheung Ka-Chun, Deneer Vera Hm, Dupui Mathilde, Ingelman-Sundberg Magnus, Jonsson Siv, Joefield-Roka Candace, Just Katja S, Karlsson Mats O, Konta Lidija, Koopmann Rudolf, Kriek Marjolein, Lehr Thorsten, Mitropoulou Christina, Rial-Sebbag Emmanuelle, Rollinson Victoria, Roncato Rossana, Samwald Matthias, Schaeffeler Elke, Skokou Maria, Schwab Matthias, Steinberger Daniela, Stingl Julia C, Tremmel Roman, Turner Richard M, van Rhenen Mandy H, Dávila Fajardo Cristina L, Dolžan Vita, Patrinos George P, Pirmohamed Munir, Sunder-Plassmann Gere, Toffoli Giuseppe, Guchelaar Henk-Jan and Ubiquitous Pharmacogenomics Consortium.
    PGx Paper Type: Implementation, Uses PharmGKB
    Literature
    Identifying the prevalence of clinically actionable drug-gene interactions in a health system biorepository to guide pharmacogenetics implementation services.
    Clinical and translational science. 2023. Pasternak Amy L, Ward Kristen, Irwin Madison, Okerberg Carl, Hayes David, Fritsche Lars, Zoellner Sebastian, Virzi Jessica, Choe Hae Mi and Ellingrod Vicki.
    PGx Paper Type: Implementation
    Literature
    Breast cancer pharmacogenetics: a systematic review.
    Pharmacogenomics. 2023. Scudeler Mariana M, Manóchio Caíque, Braga Pinto Alex J, Santos Cirino Heithor Dos, da Silva Cléber S and Rodrigues-Soares Fernanda.
    PGx Paper Type: Review
    Literature
    DPYD genotyping and predicting fluoropyrimidine toxicity: where do we stand?
    Pharmacogenomics. 2023. Lešnjaković Lucija, Ganoci Lana, Bilić Ivan, Šimičević Livija, Mucalo Iva, Pleština Stjepko and Božina Nada.
    PGx Paper Type: Implementation, Review
    Literature
    Case report: 5-Fluorouracil treatment in patient with an important partial DPD deficiency.
    Frontiers in oncology. 2023. Schmitt Antonin, Royer Bernard, Boidot Romain, Berthier Joseph and Ghiringhelli François.
    Literature
    Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia.
    Frontiers in pharmacology. 2023. Wu Angela, Anderson Helen, Hughesman Curtis, Young Sean, Lohrisch Caroline, Ross Colin J D and Carleton Bruce C.
    PGx Paper Type: Implementation
    Literature
    Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in Greece.
    Frontiers in pharmacology. 2023. Ragia Georgia, Maslarinou Anthi, Atzemian Natalia, Biziota Eirini, Koukaki Triantafyllia, Ioannou Charalampia, Balgkouranidou Ioanna, Kolios George, Kakolyris Stylianos, Xenidis Nikolaos, Amarantidis Kyriakos and Manolopoulos Vangelis G.
    PGx Paper Type: Implementation
    Literature
    Pharmacogenetic Practice of Anticancer Drugs: Multiple Approaches for an Accurate and Comprehensive Genotyping.
    Pharmacogenomics and personalized medicine. 2023. Montrasio Cristina, Cheli Stefania and Clementi Emilio.
    PGx Paper Type: Implementation, Methods, Uses PharmGKB
    Literature
    Dihydropyrimidine dehydrogenase (DPD) genotype and phenotype among Danish cancer patients: prevalence and correlation between DPYD-genotype variants and P-uracil concentrations.
    Acta oncologica (Stockholm, Sweden). 2022. Paulsen Niels Herluf, Qvortrup Camilla, Vojdeman Fie Juhl, Plomgaard Peter, Andersen Stig Ejdrup, Ramlov Anne, Bertelsen Birgitte, Rossing Maria, Nielsen Claus Gyrup, Hoffmann-Lücke Elke, Greibe Eva, Spangsberg Holm Hanne, Nielsen Heidi Hvid, Lolas Ihab Bishara Yousef, Madsen Jonna Skov, Bergmann Marianne Lerbaek, Mørk Morten, Fruekilde Palle B Nielsen, Bøttger Pernille, Petersen Peter Clausager, Nissen Peter Henrik, Feddersen Søren, Bergmann Troels K, Pfeiffer Per and Damkier Per.
    PGx Paper Type: Implementation, Methods
    Literature
    Pharmacogenomics of medications given via nonconventional administration routes: a scoping review.
    Pharmacogenomics. 2022. Socco Samantha, Wake Dyson T, Lee James C and Dunnenberger Henry M.
    PGx Paper Type: Implementation, Review
    Literature
    From Genes to Endogenous Substrates: Towards a Better Understanding of Drug Metabolizing Enzymes.
    Clinical pharmacology and therapeutics. 2022. Chung Cecilia P.
    PGx Paper Type: Editorial
    Literature
    Impact of Guidelines Regarding Dihydropyrimidine Dehydrogenase (DPD) Deficiency Screening Using Uracil-Based Phenotyping on the Reduction of Severe Side Effect of 5-Fluorouracil-Based Chemotherapy: A Propension Score Analysis.
    Pharmaceutics. 2022. Laures Nicolas, Konecki Céline, Brugel Mathias, Giffard Anne-Lise, Abdelli Naceur, Botsen Damien, Carlier Claire, Gozalo Claire, Feliu Catherine, Slimano Florian, Djerada Zoubir and Bouché Olivier.
    PGx Paper Type: Implementation, Methods
    Literature
    Detection of relevant pharmacogenetic information through exome sequencing in oncology.
    Pharmacogenomics. 2022. Verdez Simon, Albuisson Juliette, Duffourd Yannis, Boidot Romain, Reda Manon, Thauvin-Robinet Christel, Fumet Jean-David, Ladoire Sylvain, Nambot Sophie, Callier Patrick, Faivre Laurence, Ghiringhelli François and Picard Nicolas.
    PGx Paper Type: Implementation
    Literature
    Evaluation of TS and ENOSF1 Variants as a Biomarker in Response to Neoadjuvant Chemotherapy based on 5FU in Gastric Cancer Patients.
    Asian Pacific journal of cancer prevention : APJCP. 2022. Arjmandi Khadijeh, Ameli Fereshteh, Salahshourifar Iman, Esfandbod Mhsen and Irani Shiva.
    Literature
    Genotype-based chemotherapy for patients with gastrointestinal tumors: focus on oxaliplatin, irinotecan, and fluoropyrimidines.
    Drug metabolism and personalized therapy. 2022. Fedorinov Denis S, Lyadov Vladimir K and Sychev Dmitriy A.
    PGx Paper Type: Review, Pharmacoeconomics
    Literature
    MTHFR c.665C>T guided fluoropyrimidine therapy in cancer: gender-dependent effect on dose requirements.
    Drug metabolism and personalized therapy. 2022. Ioannou Charalampia, Ragia Georgia, Balgkouranidou Ioanna, Xenidis Nikolaos, Amarantidis Kyriakos, Koukaki Triantafyllia, Biziota Eirini, Kakolyris Stylianos and Manolopoulos Vangelis G.
    Literature
    Pharmacogenetic Study of the Dihydropyridine Dehydrogenase Gene in Jordanian Patients with Colorectal Cancer.
    Asian Pacific journal of cancer prevention : APJCP. 2022. Almashagbah Nusaiba A, Mahasneh Amjad A and Bodoor Khaldon G.
    Literature
    Assessment of Drug-drug Interaction and Optimization in Capecitabine and Irinotecan Combination Regimen using a Physiologically Based Pharmacokinetic Model.
    Journal of pharmaceutical sciences. 2022. Sakai Shuhei, Kobuchi Shinji, Ito Yukako and Sakaeda Toshiyuki.
    PGx Paper Type: Methods
    Literature
    Drugs@FDA: Drug Product Carac (fluorouracil), Bausch Health US, LLC - NDA020985/SUPPL-19, 05/26/2022
    2022.
    Literature
    5-Fluorouracil Neurotoxicity in the Absence of Dihydropyrimidine Dehydrogenase Deficiency Case Report.
    The Neurohospitalist. 2022. Jules Rebecca, Thaper Arushi, Foster Ryan, Ameli Pouya, Robinson Christopher, Pizzi Michael, Babi Marc-Alain, Maciel Carolina B, Busl Katharina M, Reddy Raju and Roth William.
    Literature
    Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2022. García-Alfonso P, Saiz-Rodríguez M, Mondéjar R, Salazar J, Páez D, Borobia A M, Safont M J, García-García I, Colomer R, García-González X, Herrero M J, López-Fernández L A and Abad-Santos F.
    Literature
    Pharmacogenetics of Drugs Used in the Treatment of Cancers.
    Genes. 2022. Franczyk Beata, Rysz Jacek and Gluba-Brzózka Anna.
    PGx Paper Type: Review
    Literature
    Dihydropyrimidine dehydrogenase (DPD) polymorphisms knocking on the door.
    Ecancermedicalscience. 2022. Donadio Mauro Daniel Spina, Carraro Dirce Maria, Torrezan Giovana Tardin and de Mello Celso Abdon Lopes.
    PGx Paper Type: Implementation, Review, Pharmacoeconomics
    Literature
    Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance).
    Pharmacogenetics and genomics. 2021. Patel Jai N, Jiang Chen, Owzar Kouros, Mulkey Flora, Luzum Jasmine A, Mamon Harvey J, Haller Daniel G, Dragovich Tomislav, Alberts Steven R, Bjarnason Georg, Willet Christopher G, Niedzwiecki Donna, Enzinger Peter, Ratain Mark J, Fuchs Charles and McLeod Howard L.
    Literature
    Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase ( DPYD) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study.
    Pharmaceutics. 2021. Soria-Chacartegui Paula, Villapalos-García Gonzalo, López-Fernández Luis A, Navares-Gómez Marcos, Mejía-Abril Gina, Abad-Santos Francisco and Zubiaur Pablo.
    Literature
    A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer.
    BMC cancer. 2021. Cordova-Delgado Miguel, Bravo María Loreto, Cumsille Elisa, Hill Charlotte N, Muñoz-Medel Matías, Pinto Mauricio P, Retamal Ignacio N, Lavanderos María A, Miquel Juan Francisco, Rodriguez-Fernandez Maria, Liao Yuwei, Li Zhiguang, Corvalán Alejandro H, Armisén Ricardo, Garrido Marcelo, Quiñones Luis A and Owen Gareth I.
    Literature
    Mucinous and non-mucinous colorectal cancers show differential expression of chemotherapy metabolism and resistance genes.
    The pharmacogenomics journal. 2021. O'Connell E, Reynolds I S, Salvucci M, McNamara D A, Burke J P and Prehn J H M.
    Literature
    Gender-dependent association of TYMS-TSER polymorphism with 5-fluorouracil or capecitabine-based chemotherapy toxicity.
    Pharmacogenomics. 2021. Ioannou Charalampia, Ragia Georgia, Balgkouranidou Ioanna, Xenidis Nikolaos, Amarantidis Kyriakos, Koukaki Triantafyllia, Biziota Eirini, Kakolyris Stylianos and Manolopoulos Vangelis G.
    Literature
    Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events.
    Clinical and translational science. 2021. Wigle Theodore J, Povitz Brandi L, Medwid Samantha, Teft Wendy A, Legan Robin M, Lenehan John, Nevison Stephanie, Panuganty Veera, Keller Denise, Mailloux Jaymie, Siebring Victoria, Sarma Sisira, Choi Yun-Hee, Welch Stephen, Winquist Eric, Schwarz Ute I and Kim Richard B.
    Literature
    Role of Genetic Variation in Cytochromes P450 in Breast Cancer Prognosis and Therapy Response.
    International journal of molecular sciences. 2021. Hlaváč Viktor, Václavíková Radka, Brynychová Veronika, Ostašov Pavel, Koževnikovová Renata, Kopečková Katerina, Vrána David, Gatěk Jiří and Souček Pavel.
    Literature
    Patients carrying DPYD variant alleles have increased risk of severe toxicity and related treatment modifications during fluoropyrimidine chemotherapy.
    Pharmacogenomics. 2021. Shakeel Faisal, Fang Fang, Kwon Jung Won, Koo Kyoin, Pasternak Amy L, Henry N Lynn, Sahai Vaibhav, Kidwell Kelley M and Hertz Daniel L.
    Literature
    DPYD Genotyping in Patients Who Have Planned Cancer Treatment With Fluoropyrimidines: A Health Technology Assessment.
    Ontario health technology assessment series. 2021. Ontario Health (Quality).
    PGx Paper Type: Implementation, Review, Pharmacoeconomics
    Literature
    Unraveling heterogeneity of the clinical pharmacogenomic guidelines in oncology practice among major regulatory bodies.
    Pharmacogenomics. 2020. Nagy Mohamed, Attya Mohamed and Patrinos George P.
    Literature
    Implementation of a pharmacogenomic program in a Brazilian public institution.
    Pharmacogenomics. 2020. Suarez-Kurtz Guilherme, Kovaleski Giovana, Elias Anna Br, Motta Vera LA, Wolch Karolyne, Emerenciano Mariana, Mansur Marcela B, Palladino Alexandre M, Accioly Maria T, Ferreira Marcos, Gonçalves Antonio A and de Melo Andréia C.
    Literature
    Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines.
    European journal of human genetics : EJHG. 2020. Lunenburg Carin A T C, van der Wouden Cathelijne H, Nijenhuis Marga, Crommentuijn-van Rhenen Mandy H, de Boer-Veger Nienke J, Buunk Anne Marie, Houwink Elisa J F, Mulder Hans, Rongen Gerard A, van Schaik Ron H N, van der Weide Jan, Wilffert Bob, Deneer Vera H M, Swen Jesse J and Guchelaar Henk-Jan.
    PGx Paper Type: Implementation
    Literature
    Pharmacogenetic guidelines of The ITALIAN ASSOCIATION of Medical Oncology ASSOCIAZIONE ITALIANA di Oncologia Medica, AIOM
    2020.
    PGx Paper Type: Implementation, Uses PharmGKB
    Literature
    Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.
    International journal of cancer. 2019. Henricks Linda M, van Merendonk Lisanne N, Meulendijks Didier, Deenen Maarten J, Beijnen Jos H, de Boer Anthonius, Cats Annemieke and Schellens Jan H M.
    PGx Paper Type: Implementation
    Literature
    Genetics and adverse events with irinotecan treatment: what do we know?
    Pharmacogenomics. 2019. Páez David.
    Literature
    Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma.
    Pharmacogenomics. 2019. Zemanek Tomas, Melichar Bohuslav, Lovecek Martin, Soucek Pavel and Mohelnikova-Duchonova Beatrice.
    Literature
    DPD Testing Before Treatment With Fluoropyrimidines in the Amsterdam UMCs: An Evaluation of Current Pharmacogenetic Practice.
    Frontiers in pharmacology. 2019. Martens Forike K, Huntjens Daan W, Rigter Tessel, Bartels Meike, Bet Pierre M and Cornel Martina C.
    Literature
    Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers.
    European journal of cancer (Oxford, England : 1990). 2018. Lunenburg Carin A T C, Henricks Linda M, Dreussi Eva, Peters Femke P, Fiocco Marta, Meulendijks Didier, Toffoli Giuseppe, Guchelaar Henk-Jan, Swen Jesse J, Cecchin Erika, Schellens Jan H M and Gelderblom Hans.
    PGx Paper Type: Implementation
    Literature
    Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase.
    Clinical pharmacology and therapeutics. 2018. Shrestha Shikshya, Zhang Cheng, Jerde Calvin R, Nie Qian, Li Hu, Offer Steven M and Diasio Robert B.
    Literature
    Functional Characterization of 21 Allelic Variants of Dihydropyrimidine Dehydrogenase Identified in 1070 Japanese Individuals.
    Drug metabolism and disposition: the biological fate of chemicals. 2018. Hishinuma Eiji, Narita Yoko, Saito Sakae, Maekawa Masamitsu, Akai Fumika, Nakanishi Yuya, Yasuda Jun, Nagasaki Masao, Yamamoto Masayuki, Yamaguchi Hiroaki, Mano Nariyasu, Hirasawa Noriyasu and Hiratsuka Masahiro.
    Literature
    The 9p21 locus as a potential therapeutic target and prognostic marker in colorectal cancer.
    Pharmacogenomics. 2018. Bahrami Afsane, Hassanian Seyed Mahdi, Khazaei Majid, Gharib Masoumeh, Rahmani Mahsa, Fiuji Hamid, Jazayeri Mir Hadi, Moetamani-Ahmadi Mehrdad, Ferns Gordon A and Avan Amir.
    Literature
    Improving decision making on DPYD and UGT1A1*28 patients' profiling with an innovative reimbursement strategy.
    Pharmacogenomics. 2018. Roncato Rossana, Cecchin Erika and Toffoli Giuseppe.
    Literature
    The Genomic Landscape and Pharmacogenomic Interactions of Clock Genes in Cancer Chronotherapy.
    Cell systems. 2018. Ye Youqiong, Xiang Yu, Ozguc Fatma Muge, Kim Yoonjin, Liu Chun-Jie, Park Peter K, Hu Qingsong, Diao Lixia, Lou Yanyan, Lin Chunru, Guo An-Yuan, Zhou Bingying, Wang Li, Chen Zheng, Takahashi Joseph S, Mills Gordon B, Yoo Seung-Hee and Han Leng.
    Literature
    Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.
    Clinical pharmacology and therapeutics. 2018. Amstutz Ursula, Henricks Linda M, Offer Steven M, Barbarino Julia, Schellens Jan H M, Swen Jesse J, Klein Teri E, McLeod Howard L, Caudle Kelly E, Diasio Robert B and Schwab Matthias.
    PGx Paper Type: Implementation
    Literature
    Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients.
    Oncotarget. 2018. Tecza Karolina, Pamula-Pilat Jolanta, Lanuszewska Joanna, Butkiewicz Dorota and Grzybowska Ewa.
    Literature
    Clinical Value of Pharmacogenomic Testing in a Patient Receiving FOLFIRINOX for Pancreatic Adenocarcinoma.
    Frontiers in pharmacology. 2018. Velez-Velez Lisa M, Hughes Caren L and Kasi Pashtoon Murtaza.
    PGx Paper Type: Implementation
    Literature
    The response to neoadjuvant chemoradiotherapy with 5-fluorouracil in locally advanced rectal cancer patients: a predictive proteomic signature.
    Clinical proteomics. 2018. Chauvin Anaïs, Wang Chang-Shu, Geha Sameh, Garde-Granger Perrine, Mathieu Alex-Ane, Lacasse Vincent and Boisvert François-Michel.
    Literature
    Uridine triacetate for severe 5-fluorouracil toxicity in a patient with thymidylate synthase gene variation: Potential pharmacogenomic implications.
    SAGE open medical case reports. 2018. Baldeo Candice, Vishnu Prakash, Mody Kabir and Kasi Pashtoon Murtaza.
    Literature
    Functional genetic variants of XRCC4 and ERCC1 predict survival of gastric cancer patients treated with chemotherapy by regulating the gene expression.
    Molecular carcinogenesis. 2017. Cheng Lei, Qiu Lixin, Wang Mengyun, Zhang Ruoxin, Sun Menghong, Zhu Xiaodong, Wang Yanong and Wei Qingyi.
    Literature
    Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research. 2017. Smyth Elizabeth, Zhang Shenli, Cunningham David, Wotherspoon Andrew, Soong Richie, Peckitt Clare, Valeri Nicola, Fassan Matteo, Rugge Massimo, Okines Alicia, Allum William, Stenning Sally, Nankivell Matthew, Langley Ruth and Tan Patrick.
    Literature
    Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity.
    Oncotarget. 2017. Fasching Peter A, Häberle Lothar, Rack Brigitte, Li Liang, Hein Alexander, Ekici Arif B, Reis Andre, Lux Michael P, Cunningham Julie M, Ruebner Matthias, Jenkins Gergory, Fridley Brooke, Schneeweiss Andreas, Tesch Hans, Lichtenegger Werner, Fehm Tanja, Heinrich Georg, Rezai Mahdi, Beckmann Matthias W, Janni Wolfgang, Weinshilboum Richard M and Wang Liewei.
    Literature
    The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems.
    Clinical pharmacology and therapeutics. 2017. Luzum J A, Pakyz R E, Elsey A R, Haidar C E, Peterson J F, Whirl-Carrillo M, Handelman S K, Palmer K, Pulley J M, Beller M, Schildcrout J S, Field J R, Weitzel K W, Cooper-DeHoff R M, Cavallari L H, O'Donnell P H, Altman R B, Pereira N, Ratain M J, Roden D M, Embi P J, Sadee W, Klein T E, Johnson J A, Relling M V, Wang L, Weinshilboum R M, Shuldiner A R, Freimuth R R and Pharmacogenomics Research Network Translational Pharmacogenetics Program.
    Literature
    Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer.
    Scientific reports. 2017. Del Re Marzia, Vivaldi Caterina, Rofi Eleonora, Vasile Enrico, Miccoli Mario, Caparello Chiara, d'Arienzo Paolo Davide, Fornaro Lorenzo, Falcone Alfredo and Danesi Romano.
    Literature
    SPARC gene variants predict clinical outcome in locally advanced and metastatic pancreatic cancer patients.
    Medical oncology (Northwood, London, England). 2017. Arqueros Cristina, Salazar Juliana, Arranz M J, Sebio Ana, Mora Josefina, Sullivan Ivana, Tobeña María, Martín-Richard Marta, Barnadas Agustí, Baiget Montserrat and Páez David.
    Literature
    MicroRNAs as a tool to aid stratification of colorectal cancer patients and to guide therapy.
    Pharmacogenomics. 2017. Goblirsch Matthew, Richtig Georg, Slaby Ondrej, Berindan-Neagoe Ioana, Gerger Armin and Pichler Martin.
    Literature
    The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity.
    The pharmacogenomics journal. 2017. Hamzic S, Wenger N, Froehlich T K, Joerger M, Aebi S, Largiadèr C R and Amstutz U.
    Pediatric
    Literature
    A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient.
    Anti-cancer drugs. 2017. Botticelli Andrea, Onesti Concetta E, Strigari Lidia, Occhipinti Mario, Di Pietro Francesca R, Cerbelli Bruna, Petremolo Antonella, Anselmi Elisabetta, Macrini Serena, Roberto Michela, Falcone Rosa, Lionetto Luana, Borro Marina, Milano Annalisa, Gentile Giovanna, Simmaco Maurizio, Marchetti Paolo and Mazzuca Federica.
    PGx Paper Type: Implementation
    Literature
    Association of thymidylate synthase polymorphisms with the tumor response to preoperative chemoradiotherapy in rectal cancer: a systematic review and meta-analysis.
    The pharmacogenomics journal. 2017. Yang Y C, Wu G C, Jin L, Wang K L, Bai Z G, Wang J and Zhang Z T.
    Literature
    Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.
    British journal of cancer. 2017. Meulendijks Didier, Henricks Linda M, Jacobs Bart A W, Aliev Abidin, Deenen Maarten J, de Vries Niels, Rosing Hilde, van Werkhoven Erik, de Boer Anthonius, Beijnen Jos H, Mandigers Caroline M P W, Soesan Marcel, Cats Annemieke and Schellens Jan H M.
    Literature
    Association of genetic variability in enzymes metabolizing chemotherapeutic agents with treatment response in head and neck cancer cases.
    Asia-Pacific journal of clinical oncology. 2017. Dhawan Ankur, Ruwali Munindra, Pant Mohan C, Rahman Qamar and Parmar Devendra.
    Literature
    Pharmacogenetics of anti-cancer drugs: State of the art and implementation - recommendations of the French National Network of Pharmacogenetics.
    Therapie. 2017. Quaranta Sylvie and Thomas Fabienne.
    Literature
    Correlative analysis of plasma SN-38 levels and DPD activity with outcomes of FOLFIRI regimen for metastatic colorectal cancer with UGT1A1 *28 and *6 wild type and its implication for individualized chemotherapy.
    Cancer biology & therapy. 2017. Cai Xun, Tian Chuan, Wang Liwei, Zhuang Rongyuan, Zhang Xiaowei, Guo Yuanbiao, Lu Hongmin, Wang Hui, Li Xiaoyu, Gao Junwei, Li Qi and Wang Chungang.
    Literature
    Novel Deleterious Dihydropyrimidine Dehydrogenase Variants May Contribute to 5-Fluorouracil Sensitivity in an East African Population.
    Clinical pharmacology and therapeutics. 2017. Elraiyah T, Jerde C R, Shrestha S, Wu R, Nie Q, Giama N H, Sarangi V, Roberts L R, Offer S M and Diasio R B.
    Literature
    A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification.
    Seminars in oncology. 2017. Boisdron-Celle Michèle, Metges Jean Philippe, Capitain Olivier, Adenis Antoine, Raoul Jean Luc, Lecomte Thierry, Lam You Heng, Faroux Roger, Masliah Claude, Poirier Anne Lise, Berger Virginie, Morel Alain and Gamelin Erick.
    PGx Paper Type: Implementation
    Literature
    Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer.
    Oncotarget. 2017. Borro Marina, Botticelli Andrea, Mazzuca Federica, Onesti Elisa Concetta, Gentile Giovanna, Romiti Adriana, Cerbelli Bruna, Mazzotti Eva, Marchetti Luca, Lionetto Luana, Simmaco Maurizio and Marchetti Paolo.
    Literature
    Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.
    Seminars in oncology. 2017. Boisdron-Celle Michele, Capitain Olivier, Faroux Roger, Borg Christophe, Metges Jean Philippe, Galais Marie Pierre, Kaassis Mehdi, Bennouna Jaafar, Bouhier-Leporrier Karine, Francois Eric, Baumgaertner Isabelle, Guerin-Meyer Véronique, Cojocarasu Oana, Roemer-Becuwe Celia, Stampfli Claire, Rosenfeld Ludovic, Lecompte Thierry, Berger Virginie, Morel Alain and Gamelin Erick.
    PGx Paper Type: Implementation
    Literature
    GSTP1, GSTM1, and GSTT1 polymorphisms as predictors of response to chemotherapy in patients with breast cancer: a meta-analysis.
    Cancer chemotherapy and pharmacology. 2016. Kong Xiangzhen, Li Zihao and Li Xian.
    Literature
    Pancytopenia and Severe Gastrointestinal Toxicities Associated with 5-Fluorouracil in a Patient with Thymidylate Synthase (TYMS) Polymorphism.
    Cureus. 2016. Wang Bo, Walsh Shannon J and Saif Muhammad W.
    Literature
    Suppression of TWIST1 enhances the sensitivity of colon cancer cells to 5-fluorouracil.
    The international journal of biochemistry & cell biology. 2016. Sakowicz-Burkiewicz Monika, Przybyla Tomasz, Wesserling Martyna, Bielarczyk Hanna, Maciejewska Izabela and Pawelczyk Tadeusz.
    Literature
    Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients.
    Pharmacogenomics. 2016. Lunenburg Carin Atc, van Staveren Maurice C, Gelderblom Hans, Guchelaar Henk-Jan and Swen Jesse J.
    PGx Paper Type: Implementation
    Literature
    Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort.
    Oncotarget. 2016. Mazzuca Federica, Borro Marina, Botticelli Andrea, Mazzotti Eva, Marchetti Luca, Gentile Giovanna, La Torre Marco, Lionetto Luana, Simmaco Maurizio and Marchetti Paolo.
    Literature
    Fluoropyrimidine and platinum toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.
    Pharmacogenomics. 2016. Campbell Jared M, Bateman Emma, Peters Micah Dj, Bowen Joanne M, Keefe Dorothy M and Stephenson Matthew D.
    Literature
    GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization.
    Pharmacogenomics. 2016. Liang Kung-Hao, Lin Chih-Lang, Chen Sung-Fang, Chiu Chih-Wei, Yang Pei-Ching, Chang Ming-Ling, Lin Chen-Chun, Sung Kai-Feng, Yeh Cassandra, Hung Chien-Fu, Chien Rong-Nan and Yeh Chau-Ting.
    Literature
    Integrated patient and tumor genetic testing for individualized cancer therapy.
    Clinical pharmacology and therapeutics. 2016. Hertz D L and McLeod H L.
    Literature
    Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.
    European journal of cancer (Oxford, England : 1990). 2016. Lunenburg Carin A T C, Henricks Linda M, Guchelaar Henk-Jan, Swen Jesse J, Deenen Maarten J, Schellens Jan H M and Gelderblom Hans.
    Literature
    Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer.
    British journal of clinical pharmacology. 2016. Launay Manon, Dahan Laetitia, Duval Manon, Rodallec Anne, Milano Gérard, Duluc Muriel, Lacarelle Bruno, Ciccolini Joseph and Seitz Jean-Francois.
    Literature
    Pharmacogenetics driving personalized medicine: analysis of genetic polymorphisms related to breast cancer medications in Italian isolated populations.
    Journal of translational medicine. 2016. Cocca Massimiliano, Bedognetti Davide, La Bianca Martina, Gasparini Paolo and Girotto Giorgia.
    Literature
    Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016. Deenen Maarten J, Meulendijks Didier, Cats Annemieke, Sechterberger Marjolein K, Severens Johan L, Boot Henk, Smits Paul H, Rosing Hilde, Mandigers Caroline M P W, Soesan Marcel, Beijnen Jos H and Schellens Jan H M.
    PGx Paper Type: Implementation
    Literature
    Pharmacogenomically actionable medications in a safety net health care system.
    SAGE open medicine. 2016. Carpenter Janet S, Rosenman Marc B, Knisely Mitchell R, Decker Brian S, Levy Kenneth D and Flockhart David A.
    Literature
    BRAF in metastatic colorectal cancer: the future starts now.
    Pharmacogenomics. 2015. Orlandi Armando, Calegari Alessandra, Inno Alessandro, Berenato Rosa, Caporale Marta, Niger Monica, Bossi Ilaria, Di Bartolomeo Maria, de Braud Filippo and Pietrantonio Filippo.
    Literature
    Germ line polymorphisms as predictive markers for pre-surgical radiochemotherapy in locally advanced rectal cancer: a 5-year literature update and critical review.
    European journal of clinical pharmacology. 2015. Pezzolo Elisa, Modena Yasmina, Corso Barbara, Giusti Pietro and Gusella Milena.
    Literature
    Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation.
    Clinical cancer research : an official journal of the American Association for Cancer Research. 2015. Bohanes Pierre, Rankin Cathryn J, Blanke Charles D, Winder Thomas, Ulrich Cornelia M, Smalley Stephen R, Rich Tyvin A, Martensen James A, Benson Al B, Mayer Robert J, Cripps Christine M, Danenberg Kathleen, Makar Karen W, Zhang Wu, Benedetti Jacqueline K and Lenz Heinz-Josef.
    Literature
    Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015. Van Cutsem Eric, Lenz Heinz-Josef, Köhne Claus-Henning, Heinemann Volker, Tejpar Sabine, Melezínek Ivan, Beier Frank, Stroh Christopher, Rougier Philippe, van Krieken J Han and Ciardiello Fortunato.
    Literature
    MicroRNA-494 sensitizes colon cancer cells to fluorouracil through regulation of DPYD.
    IUBMB life. 2015. Chai Jie, Dong Wei, Xie Chao, Wang Lin, Han Da-Li, Wang Shan, Guo Hong-Liang and Zhang Zong-Li.
    Literature
    Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion.
    BMC cancer. 2015. Fleming Gini F, Schumm Philip, Friberg Greg, Ratain Mark J, Njiaju Uchenna O and Schilsky Richard L.
    Literature
    Dihydropyrimidinase and beta-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity.
    Pharmacogenomics. 2015. Kummer Dominic, Froehlich Tanja K, Joerger Markus, Aebi Stefan, Sistonen Johanna, Amstutz Ursula and Largiadèr Carlo R.
    Pediatric
    Literature
    Effects of IGF2BP2, KCNQ1 and GCKR polymorphisms on clinical outcome in metastatic gastric cancer treated with EOF regimen.
    Pharmacogenomics. 2015. Liu Xin, Chen Zhiyu, Zhao Xiaoying, Huang Mingzhu, Wang Chenchen, Peng Wei, Yin Jiliang, Li Jin, He Guang, Li Xin and Zhu Xiaodong.
    Literature
    HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment.
    PloS one. 2015. Garziera Marica, Bidoli Ettore, Cecchin Erika, Mini Enrico, Nobili Stefania, Lonardi Sara, Buonadonna Angela, Errante Domenico, Pella Nicoletta, D'Andrea Mario, De Marchi Francesco, De Paoli Antonino, Zanusso Chiara, De Mattia Elena, Tassi Renato and Toffoli Giuseppe.
    Literature
    Molecular biomarkers in colorectal carcinoma.
    Pharmacogenomics. 2015. Puerta-García Elena, Cañadas-Garre Marisa and Calleja-Hernández Miguel Ángel.
    Literature
    Prognostic and predictive significance of thymidylate synthase protein expression in non-small cell lung cancer: a systematic review and meta-analysis.
    Cancer biomarkers : section A of Disease markers. 2015. Liu Qingyun, Yu Zubin, Xiang Ying, Wu Na, Wu Long, Xu Bin, Wang Liang, Yang Ping, Li Yafei and Bai Li.
    Literature
    Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score.
    Pharmacogenomics. 2015. Henricks Linda M, Lunenburg Carin A T C, Meulendijks Didier, Gelderblom Hans, Cats Annemieke, Swen Jesse J, Schellens Jan H M and Guchelaar Henk-Jan.
    PGx Paper Type: Implementation
    Literature
    Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among patients with stage II or III rectal cancer (INT-0144; SWOG 9304).
    Cancer. 2014. Ulrich Cornelia M, Rankin Cathryn, Toriola Adetunji T, Makar Karen W, Altug-Teber Özge, Benedetti Jacqueline K, Holmes Rebecca S, Smalley Stephen R, Blanke Charles D and Lenz Heinz-Josef.
    Literature
    A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy.
    The oncologist. 2014. Patel Jai N, O'Neil Bert H, Deal Allison M, Ibrahim Joseph G, Sherrill Gary B, Olajide Oludamilola A, Atluri Prashanti M, Inzerillo John J, Chay Christopher H, McLeod Howard L and Walko Christine M.
    Literature
    Pharmacogenetic research in partnership with American Indian and Alaska Native communities.
    Pharmacogenomics. 2014. Woodahl Erica L, Lesko Lawrence J, Hopkins Scarlett, Robinson Renee F, Thummel Kenneth E and Burke Wylie.
    Literature
    Role of solute carrier transporters in pancreatic cancer: a review.
    Pharmacogenomics. 2014. Lemstrová Radmila, Souček Pavel, Melichar Bohuslav and Mohelnikova-Duchonova Beatrice.
    Literature
    UGT1A1*28 polymorphisms: a potential pharmacological biomarker of irinotecan-based chemotherapies in colorectal cancer.
    Pharmacogenomics. 2014. Liu Xiang and Xu Wei.
    Literature
    Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity.
    Cancer research. 2014. Offer Steven M, Fossum Croix C, Wegner Natalie J, Stuflesser Alexander J, Butterfield Gabriel L and Diasio Robert B.
    Literature
    Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms.
    Journal of clinical pharmacology. 2014. Suenaga Mitsukuni, Fuse Nozomu, Yamaguchi Tatsuro, Yamanaka Yasuhiro, Motomura Shigeki, Matsumoto Hiroshi, Hamamoto Yasuo, Mizunuma Nobuyuki, Doi Toshihiko, Hatake Kiyohiko, Iwasaki Junko and Ohtsu Atsushi.
    Literature
    Epigenetic perspectives on cancer chemotherapy response.
    Pharmacogenomics. 2014. Liu Mou-Ze, McLeod Howard L, He Fa-Zhong, Chen Xiao-Ping, Zhou Hong-Hao, Shu Yan and Zhang Wei.
    Literature
    Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy.
    The pharmacogenomics journal. 2014. Benhaim L, Gerger A, Bohanes P, Paez D, Wakatsuki T, Yang D, Labonte M J, Ning Y, El-Khoueiry R, Loupakis F, Zhang W, Laurent-Puig P and Lenz H J.
    Literature
    A functional germline variant in GLI1 implicates hedgehog signaling in clinical outcome of stage II and III colon carcinoma patients.
    Clinical cancer research : an official journal of the American Association for Cancer Research. 2014. Szkandera Joanna, Pichler Martin, Absenger Gudrun, Stotz Michael, Weissmueller Melanie, Samonigg Hellmut, Asslaber Martin, Lax Sigurd, Leitner Gerhard, Winder Thomas, Renner Wilfried and Gerger Armin.
    Literature
    Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines.
    Pharmacogenomics. 2014. Brown Chad C, Havener Tammy M, Medina Marisa W, Jack John R, Krauss Ronald M, McLeod Howard L and Motsinger-Reif Alison A.
    Literature
    Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy.
    PloS one. 2014. De Re Valli, Caggiari Laura, De Zorzi Mariangela, Talamini Renato, Racanelli Vito, D' Andrea Mario, Buonadonna Angela, Zagonel Vittorina, Cecchin Erika, Innocenti Federico and Toffoli Giuseppe.
    Literature
    Germline variation in colorectal risk Loci does not influence treatment effect or survival in metastatic colorectal cancer.
    PloS one. 2014. Sanoff Hanna K, Renfro Lindsay A, Poonnen Pradeep, Ambadwar Pratibha, Sargent Daniel J, Goldberg Richard M and McLeod Howard.
    Literature
    Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy.
    PloS one. 2014. Geng Ruixuan, Chen Zhiyu, Zhao Xiaoying, Qiu Lixin, Liu Xin, Liu Rujiao, Guo Weijian, He Guang, Li Jin and Zhu Xiaodong.
    Literature
    Potentially functional SNPs (pfSNPs) as novel genomic predictors of 5-FU response in metastatic colorectal cancer patients.
    PloS one. 2014. Wang Jingbo, Wang Xu, Zhao Mingjue, Choo Su Pin, Ong Sin Jen, Ong Simon Y K, Chong Samuel S, Teo Yik Ying and Lee Caroline G L.
    Literature
    Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers.
    PloS one. 2014. Goff Laura W, Thakkar Nilay, Du Liping, Chan Emily, Tan Benjamin R, Cardin Dana B, McLeod Howard L, Berlin Jordan D, Zehnbauer Barbara, Fournier Chloe, Picus Joel, Wang-Gillam Andrea, Lee Wooin and Lockhart A Craig.
    Literature
    Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.
    Clinical pharmacology and therapeutics. 2013. Caudle K E, Thorn C F, Klein T E, Swen J J, McLeod H L, Diasio R B and Schwab M.
    PGx Paper Type: Implementation
    Literature
    Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib).
    The pharmacogenomics journal. 2013. Wilson P M, Yang D, Azuma M, Shi M M, Danenberg K D, Lebwohl D, Sherrod A, Ladner R D, Zhang W, Danenberg P V, Trarbach T, Folprecht G, Meinhardt G and Lenz H-J.
    Literature
    Implications of genome-wide association studies in cancer therapeutics.
    British journal of clinical pharmacology. 2013. Patel Jai N, McLeod Howard L and Innocenti Federico.
    Literature
    An individual coding polymorphism and the haplotype of the SPARC gene predict gastric cancer recurrence.
    The pharmacogenomics journal. 2013. Winder T, Wilson P M, Yang D, Zhang W, Ning Y, Power D G, Bohanes P, Gerger A, Tang L H, Shah M and Lenz H-J.
    Literature
    Common variants in genes coding for chemotherapy metabolizing enzymes, transporters, and targets: a case-control study of contralateral breast cancer risk in the WECARE Study.
    Cancer causes & control : CCC. 2013. Brooks Jennifer D, Teraoka Sharon N, Bernstein Leslie, Mellemkjær Lene, Malone Kathleen E, Lynch Charles F, Haile Robert W, Concannon Patrick, Reiner Anne S, Duggan David J, Schiermeyer Katherine, WECARE Study Collaborative Group, Bernstein Jonine L and Figueiredo Jane C.
    Literature
    Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule.
    Internal and emergency medicine. 2013. Magnani Elena, Farnetti Enrico, Nicoli Davide, Casali Bruno, Savoldi Luisa, Focaccetti Chiara, Boni Corrado, Albini Adriana and Banzi Maria.
    PGx Paper Type: Implementation
    Literature
    Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity.
    British journal of cancer. 2013. Loganayagam A, Arenas Hernandez M, Corrigan A, Fairbanks L, Lewis C M, Harper P, Maisey N, Ross P, Sanderson J D and Marinaki A M.
    Literature
    Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy.
    The pharmacogenomics journal. 2013. Pohl A, El-Khoueiry A, Yang D, Zhang W, Lurje G, Ning Y, Winder T, Hu-Lieskoven S, Iqbal S, Danenberg K D, Kahn M, Teo J-L, Shriki J, Stebbing J and Lenz H-J.
    Literature
    The expression profile of ATP-binding cassette transporter genes in breast carcinoma.
    Pharmacogenomics. 2013. Hlaváč Viktor, Brynychová Veronika, Václavíková Radka, Ehrlichová Marie, Vrána David, Pecha Václav, Koževnikovová Renata, Trnková Markéta, Gatěk Jiří, Kopperová Dana, Gut Ivan and Souček Pavel.
    Literature
    Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study.
    Cancer chemotherapy and pharmacology. 2013. Mueller F, Büchel B, Köberle D, Schürch S, Pfister B, Krähenbühl St, Froehlich T K, Largiader C R and Joerger M.
    Literature
    Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab.
    The pharmacogenomics journal. 2012. Koutras A K, Antonacopoulou A G, Eleftheraki A G, Dimitrakopoulos F-I, Koumarianou A, Varthalitis I, Fostira F, Sgouros J, Briasoulis E, Bournakis E, Bafaloukos D, Bompolaki I, Galani E, Kalogeras K T, Pectasides D, Fountzilas G and Kalofonos H P.
    Literature
    Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704.
    The pharmacogenomics journal. 2012. Farrell J J, Bae K, Wong J, Guha C, Dicker A P and Elsaleh H.
    Literature
    TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials.
    The pharmacogenomics journal. 2012. Grimminger P P, Shi M, Barrett C, Lebwohl D, Danenberg K D, Brabender J, Vigen C L P, Danenberg P V, Winder T and Lenz H-J.
    Literature
    PharmGKB summary: very important pharmacogene information for GSTT1.
    Pharmacogenetics and genomics. 2012. Thorn Caroline F, Ji Yuan, Weinshilboum Richard M, Altman Russ B and Klein Teri E.
    Literature
    Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy.
    The pharmacogenomics journal. 2012. Kim H K, Choi I J, Kim C G, Kim H S, Oshima A, Yamada Y, Arao T, Nishio K, Michalowski A and Green J E.
    Literature
    Absence of transcriptomic signature of response to chemotherapy in metastatic colorectal carcinoma patients.
    Pharmacogenomics. 2012. Laroche-Clary Audrey, Kauffmann Audrey, Smith Denis, Laurand-Quancard Armelle, Evrard Serge, Brunet René, Le Morvan Valérie and Robert Jacques.
    Literature
    A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer.
    Molecular cancer therapeutics. 2012. Allen Wendy L, Stevenson Leanne, Coyle Vicky M, Jithesh Puthen V, Proutski Irina, Carson Gail, Gordon Michael A, Lenz Heinz-Josef D, Van Schaeybroeck Sandra, Longley Daniel B and Johnston Patrick G.
    Literature
    Genomic approach towards personalized anticancer drug therapy.
    Pharmacogenomics. 2012. Midorikawa Yutaka, Tsuji Shingo, Takayama Tadatoshi and Aburatani Hiroyuki.
    Literature
    Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis.
    British journal of cancer. 2012. Tsuji S, Midorikawa Y, Takahashi T, Yagi K, Takayama T, Yoshida K, Sugiyama Y and Aburatani H.
    Literature
    X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients.
    International journal of radiation oncology, biology, physics. 2012. Lamas Maria J, Duran Goretti, Gomez Antonio, Balboa Emilia, Anido Urbano, Bernardez Beatriz, Rana-Diez Pablo, Lopez Rafael, Carracedo Angel and Barros Francisco.
    Literature
    Analysis of polymorphisms and haplotype structure of the human thymidylate synthase genetic region: a tool for pharmacogenetic studies.
    PloS one. 2012. Ghosh Soma, Hossain M Zulfiquer, Borges Michael, Goggins Michael G, Ingersoll Roxann G, Eshleman James R, Klein Alison P and Kern Scott E.
    Literature
    Contribution of the beta-ureidopropionase (UPB1) gene alterations to the development of fluoropyrimidine-related toxicity.
    Pharmacological reports : PR. 2012. Fidlerova Julie, Kleiblova Petra, Kormunda Stanislav, Novotny Jan and Kleibl Zdenek.
    Literature
    Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6.
    The oncologist. 2012. Kaldate Rajesh R, Haregewoin Abebe, Grier Charles E, Hamilton Stephanie A and McLeod Howard L.
    Literature
    Pan-pathway based interaction profiling of FDA-approved nucleoside and nucleobase analogs with enzymes of the human nucleotide metabolism.
    PloS one. 2012. Egeblad Louise, Welin Martin, Flodin Susanne, Gräslund Susanne, Wang Liya, Balzarini Jan, Eriksson Staffan and Nordlund Pär.
    Literature
    Relationship between antimetabolite toxicity and pharmacogenetics in Turkish cancer patients.
    Asian Pacific journal of cancer prevention : APJCP. 2012. Dogan Mutlu, Karabulut Halil G, Tukun Ajlan, Demirkazik Ahmet, Utkan Gungor, Yalcin Bulent, Dincol Dilek, Akbulut Hakan and Icli Fikri.
    Pediatric
    Literature
    Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan.
    The pharmacogenomics journal. 2011. Boni V, Zarate R, Villa J C, Bandrés E, Gomez M A, Maiello E, Garcia-Foncillas J and Aranda E.
    Literature
    Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer.
    British journal of cancer. 2011. Thomas F, Motsinger-Reif A A, Hoskins J M, Dvorak A, Roy S, Alyasiri A, Myerson R J, Fleshman J W, Tan B R and McLeod H L.
    Pediatric
    Literature
    Thymidylate synthase gene polymorphism affects the response to preoperative 5-fluorouracil chemoradiation therapy in patients with rectal cancer.
    International journal of radiation oncology, biology, physics. 2011. Hur Hyuk, Kang Jeonghyun, Kim Nam Kyu, Min Byung Soh, Lee Kang Young, Shin Sang Joon, Keum Ki Chang, Choi Junjeong, Kim Hoguen, Choi Sung Ho and Lee Mi-Young.
    Literature
    Pharmacogenomic characterization of US FDA-approved cytotoxic drugs.
    Pharmacogenomics. 2011. Peters Eric J, Motsinger-Reif Alison, Havener Tammy M, Everitt Lorraine, Hardison Nicholas E, Watson Venita G, Wagner Michael, Richards Kristy L, Province Mike A and McLeod Howard L.
    Literature
    SNPs and Haplotypes in DPYD and Outcome of Capecitabine-Letter.
    Clinical cancer research : an official journal of the American Association for Cancer Research. 2011. van Kuilenburg André B P and Largiadèr Carlo R.
    Literature
    The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer.
    Pharmacogenomics. 2011. Afzal Shoaib, Gusella Milena, Jensen Søren Astrup, Vainer Ben, Vogel Ulla, Andersen Jon Trærup, Brødbæk Kasper, Petersen Morten, Jimenez-Solem Espen, Adleff Vilmos, Budai Barna, Hitre Erika, Láng István, Orosz Eniko, Bertolaso Laura, Barile Carmen, Padrini Roberto, Kralovánszky Judit, Pasini Felice and Poulsen Henrik Enghusen.
    Literature
    Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil.
    Pharmacological research. 2011. Vignoli Marina, Nobili Stefania, Napoli Cristina, Putignano Anna Laura, Morganti Maria, Papi Laura, Valanzano Rosa, Cianchi Fabio, Tonelli Francesco, Mazzei Teresita, Mini Enrico and Genuardi Maurizio.
    Literature
    Association of thymidylate synthase enhancer region polymorphisms with thymidylate synthase activity in vivo.
    The pharmacogenomics journal. 2011. de Bock C E, Garg M B, Scott N, Sakoff J A, Scorgie F E, Ackland S P and Lincz L F.
    Literature
    EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients.
    Clinical cancer research : an official journal of the American Association for Cancer Research. 2011. Hu-Lieskovan Siwen, Vallbohmer Daniel, Zhang Wu, Yang Dongyun, Pohl Alexander, Labonte Melissa J, Grimminger Peter P, Hölscher Arnulf H, Semrau Robert, Arnold Dirk, Dellas Kathrin, Debucquoy Annelies, Haustermans Karin, Machiels Jean-Pascal H, Sempoux Christine, Rödel Claus, Bracko Matej, Velenik Vaneja and Lenz Heinz-Josef.
    Literature
    Genetic effects and modifiers of radiotherapy and chemotherapy on survival in pancreatic cancer.
    Pancreas. 2011. Zeng Hongmei, Yu Herbert, Lu Lingeng, Jain Dhanpat, Kidd Mark S, Saif M Wasif, Chanock Stephen J, Hartge Patricia, PanScan Consortium and Risch Harvey A.
    Literature
    VEGF -460T → C polymorphism and its association with VEGF expression and outcome to FOLFOX-4 treatment in patients with colorectal carcinoma.
    The pharmacogenomics journal. 2011. Chen M-H, Tzeng C-H, Chen P-M, Lin J-K, Lin T-C, Chen W-S, Jiang J-K, Wang H-S and Wang W-S.
    Literature
    Pharmacogenetics: from bench to byte--an update of guidelines.
    Clinical pharmacology and therapeutics. 2011. Swen J J, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee A H, Mulder H, Rongen G A P J M, van Schaik R H N, Schalekamp T, Touw D J, van der Weide J, Wilffert B, Deneer V H M and Guchelaar H-J.
    Literature
    Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes.
    Pharmacogenomics. 2011. Wang Huijuan, Bian Ting, Liu Duan, Jin Tianbo, Chen Yong, Lin Aifen and Chen Chao.
    Pediatric
    Literature
    Failure to validate toxicity and outcome biomarkers from the FFCD 2000-05 trial in the MRC CR08 FOCUS trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011. Richman Susan D, Barrett Jennifer H and Seymour Matthew T.
    Literature
    Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer.
    International journal of cancer. 2011. Nobili Stefania, Napoli Cristina, Landini Ida, Morganti Maria, Cianchi Fabio, Valanzano Rosa, Tonelli Francesco, Cortesini Camillo, Mazzei Teresita and Mini Enrico.
    Literature
    PharmGKB summary: fluoropyrimidine pathways.
    Pharmacogenetics and genomics. 2011. Thorn Caroline F, Marsh Sharon, Carrillo Michelle Whirl, McLeod Howard L, Klein Teri E and Altman Russ B.
    Literature
    Systems pharmacology assessment of the 5-fluorouracil pathway.
    Pharmacogenomics. 2011. Muhale Filipe A, Wetmore Barbara A, Thomas Russell S and McLeod Howard L.
    Literature
    Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011. Tan Benjamin R, Thomas Fabienne, Myerson Robert J, Zehnbauer Barbara, Trinkaus Kathryn, Malyapa Robert S, Mutch Matthew G, Abbey Elliot E, Alyasiry Amer, Fleshman James W and McLeod Howard L.
    Literature
    Impact of ABCB1 C3435T polymorphism on lymph node regression in multimodality treatment of locally advanced esophageal cancer.
    Pharmacogenomics. 2011. Narumiya Kosuke, Metzger Ralf, Bollschweiler Elfriede, Alakus Hakan, Brabender Jan, Drebber Uta, Hölscher Arnulf H and Warnecke-Eberz Ute.
    Literature
    Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity.
    British journal of cancer. 2011. Kim K-p, Jang G, Hong Y S, Lim H-S, Bae K-s, Kim H-S, Lee S S, Shin J-G, Lee J-L, Ryu M-H, Chang H-M, Kang Y-K and Kim T W.
    Literature
    Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer.
    The pharmacogenomics journal. 2011. Glimelius B, Garmo H, Berglund A, Fredriksson L A, Berglund M, Kohnke H, Byström P, Sørbye H and Wadelius M.
    Literature
    Associations between gene polymorphisms of thymidylate synthase with its protein expression and chemosensitivity to 5-fluorouracil in pancreatic carcinoma cells.
    Chinese medical journal. 2011. Zhang Qiang, Zhao Yu-Pei, Liao Quan, Hu Ya, Xu Qiang, Zhou Li and Shu Hong.
    Literature
    DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity.
    Cancer chemotherapy and pharmacology. 2011. Yang Chen Guang, Ciccolini Joseph, Blesius Aurore, Dahan Laetitia, Bagarry-Liegey Danielle, Brunet Caroline, Varoquaux Arthur, Frances Nicolas, Marouani Hafedh, Giovanni Antoine, Ferri-Dessens Rose-Marie, Chefrour Mohamed, Favre Roger, Duffaud Florence, Seitz Jean-François, Zanaret Michel, Lacarelle Bruno and Mercier Cédric.
    PGx Paper Type: Implementation
    Literature
    Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin.
    Pharmacogenomics. 2011. Gordon Michael A, Zhang Wu, Yang Dongyun, Iqbal Syma, El-Khouiery Anthony, Nagashima Fumio, Lurje Georg, Labonte Melissa, Wilson Peter, Sherrod Andy, Ladner Robert D and Lenz Heinz-Josef.
    Literature
    Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study.
    Anticancer research. 2011. Freyer Gilles, Duret Aude, Milano Gerard, Chatelut Etienne, Rebischung Christine, Delord Jean-Pierre, Merrouche Yacine, Lledo Gerard, Etienne Marie-Christine and Falandry Claire.
    Pediatric
    Literature
    Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application.
    The Journal of pathology. 2011. Lee Soo-Youn and McLeod Howard L.
    Literature
    Pharmacogenomic contribution to drug response.
    Cancer journal (Sudbury, Mass.). 2011. Watson Roshawn G and McLeod Howard L.
    Literature
    ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients.
    Pharmacogenomics. 2010. Gonzalez-Haba Eva, García Maria I, Cortejoso Lucia, López-Lillo Carolina, Barrueco Nélida, García-Alfonso Pilar, Alvarez Sonsoles, Jiménez Jose L, Martín María L, Muñóz-Fernández Maria A, Sanjurjo María and López-Fernández Luis A.
    Literature
    Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity.
    Human genetics. 2010. van Kuilenburg André B P, Meijer Judith, Mul Adri N P M, Meinsma Rutger, Schmid Veronika, Dobritzsch Doreen, Hennekam Raoul C M, Mannens Marcel M A M, Kiechle Marion, Etienne-Grimaldi Marie-Christine, Klümpen Heinz-Josef, Maring Jan Gerard, Derleyn Veerle A, Maartense Ed, Milano Gérard, Vijzelaar Raymon and Gross Eva.
    Literature
    Systematic review of pharmacoeconomic studies of pharmacogenomic tests.
    Pharmacogenomics. 2010. Beaulieu Mathieu, de Denus Simon and Lachaine Jean.
    Literature
    Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil.
    Journal of cancer research and clinical oncology. 2010. Páez David, Paré Laia, Altés Albert, Sancho-Poch Francesc Josep, Petriz Lourdes, Garriga Jordi, Monill Josep Maria, Salazar Juliana, del Rio Elisabeth, Barnadas Agustí, Marcuello Eugenio and Baiget Montserrat.
    Literature
    Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study.
    Cancer chemotherapy and pharmacology. 2010. Fariña-Sarasqueta Arantza, van Lijnschoten Gesina, Rutten Harm J T and van den Brule Adriaan J C.
    Literature
    Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy.
    Cancer epidemiology. 2010. Henríquez-Hernández Luis Alberto, Murias-Rosales Adolfo, González-Hernández Ana, de León Antonio Cabrera, Díaz-Chico Nicolás and Fernández-Pérez Leandro.
    Literature
    Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy.
    Pharmacogenomics. 2010. Graziano Francesco, Ruzzo Annamaria, Canestrari Emanuele, Catalano Vincenzo, Santini Daniele, Galluccio Nadia, Loupakis Fotios, Alessandroni Paolo, Spada Daniele, Ficarelli Rita, Bisonni Renato, D'Emidio Silvia, Vincenzi Bruno, Angeletti Silvia, Salvatore Lisa, Cremolini Chiara, Tonini Giuseppe, Falcone Alfredo and Magnani Mauro.
    Literature
    Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients.
    BMC cancer. 2010. Savva-Bordalo Joana, Ramalho-Carvalho João, Pinheiro Manuela, Costa Vera L, Rodrigues Angelo, Dias Paula C, Veiga Isabel, Machado Manuela, Teixeira Manuel R, Henrique Rui and Jerónimo Carmen.
    Literature
    Formation pathways of gamma-butyrolactone from the furan ring of tegafur during its conversion to 5-fluorouracil.
    Drug metabolism and disposition: the biological fate of chemicals. 2010. Yamamiya Ikuo, Yoshisue Kunihiro, Matsushima Eiji and Nagayama Sekio.
    Literature
    Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010. McLeod Howard L, Sargent Daniel J, Marsh Sharon, Green Erin M, King Cristi R, Fuchs Charles S, Ramanathan Ramesh K, Williamson Stephen K, Findlay Brian P, Thibodeau Stephen N, Grothey Axel, Morton Roscoe F and Goldberg Richard M.
    Literature
    Drug transporter pharmacogenetics in nucleoside-based therapies.
    Pharmacogenomics. 2010. Errasti-Murugarren Ekaitz and Pastor-Anglada Marçal.
    Literature
    GSTT1, GSTM1, and GSTP1 polymorphisms and chemotherapy response in locally advanced breast cancer.
    Genetics and molecular research : GMR. 2010. Oliveira A L, Rodrigues F F O, Santos R E, Aoki T, Rocha M N, Longui C A and Melo M B.
    Literature
    Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010. Boige Valérie, Mendiboure Jean, Pignon Jean-Pierre, Loriot Marie-Anne, Castaing Marine, Barrois Michel, Malka David, Trégouët David-Alexandre, Bouché Olivier, Le Corre Delphine, Miran Isabelle, Mulot Claire, Ducreux Michel, Beaune Philippe and Laurent-Puig Pierre.
    Literature
    Human lymphoblastoid cell line panels: novel tools for assessing shared drug pathways.
    Pharmacogenomics. 2010. Morag Ayelet, Kirchheiner Julia, Rehavi Moshe and Gurwitz David.
    Literature
    Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene.
    Clinical biochemistry. 2010. Ofverholm Anna, Arkblad Eva, Skrtic Stanko, Albertsson Per, Shubbar Emman and Enerbäck Charlotta.
    Literature
    Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.
    British journal of clinical pharmacology. 2010. Etienne-Grimaldi Marie-Christine, Milano Gérard, Maindrault-Goebel Frédérique, Chibaudel Benoist, Formento Jean-Louis, Francoual Mireille, Lledo Gérard, André Thierry, Mabro May, Mineur Laurent, Flesch Michel, Carola Elisabeth and de Gramont Aimery.
    Literature
    TaqMan low-density arrays and analysis by artificial neuronal networks predict response to neoadjuvant chemoradiation in esophageal cancer.
    Pharmacogenomics. 2010. Warnecke-Eberz Ute, Metzger Ralf, Bollschweiler Elfriede, Baldus Stephan E, Mueller Rolf P, Dienes Hans P, Hoelscher Arnulf H and Schneider Paul M.
    Literature
    Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.
    Breast cancer research : BCR. 2010. Gor Priya P, Su H Irene, Gray Robert J, Gimotty Phyllis A, Horn Michelle, Aplenc Richard, Vaughan William P, Tallman Martin S, Rebbeck Timothy R and DeMichele Angela.
    Literature
    Genetic polymorphisms associated with 5-Fluorouracil-induced neurotoxicity.
    Chemotherapy. 2010. Kim Suk-Ran, Park Chang-Hun, Park Silvia, Park Joon-Oh, Lee Jeeyun and Lee Soo-Youn.
    Literature
    Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics.
    Transactions of the American Clinical and Climatological Association. 2010. Goldberg Richard M, Sargent Daniel J and McLeod Howard.
    Literature
    Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients.
    The Journal of international medical research. 2010. Kristensen M H, Pedersen P L, Melsen G V, Ellehauge J and Mejer J.
    Literature
    MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology. 2009. Afzal S, Jensen S A, Vainer B, Vogel U, Matsen J P, Sørensen J B, Andersen P K and Poulsen H E.
    Literature
    Involvement of N-acetyltransferase human in the cytotoxic activity of 5-fluorouracil.
    Anti-cancer drugs. 2009. Takubo Kazuko, Tsuchiya Hiroyuki, Kurimasa Akihiro, Arnesen Thomas, Ryoke Kazuo and Shiota Goshi.
    Literature
    The increasing role of pharmacogenetics in the treatment of gastrointestinal cancers.
    Gastrointestinal cancer research : GCR. 2009. Yalçin Suayib.
    Literature
    A highly annotated whole-genome sequence of a Korean individual.
    Nature. 2009. Kim Jong-Il, Ju Young Seok, Park Hansoo, Kim Sheehyun, Lee Seonwook, Yi Jae-Hyuk, Mudge Joann, Miller Neil A, Hong Dongwan, Bell Callum J, Kim Hye-Sun, Chung In-Soon, Lee Woo-Chung, Lee Ji-Sun, Seo Seung-Hyun, Yun Ji-Young, Woo Hyun Nyun, Lee Heewook, Suh Dongwhan, Lee Seungbok, Kim Hyun-Jin, Yavartanoo Maryam, Kwak Minhye, Zheng Ying, Lee Mi Kyeong, Park Hyunjun, Kim Jeong Yeon, Gokcumen Omer, Mills Ryan E, Zaranek Alexander Wait, Thakuria Joseph, Wu Xiaodi, Kim Ryan W, Huntley Jim J, Luo Shujun, Schroth Gary P, Wu Thomas D, Kim HyeRan, Yang Kap-Seok, Park Woong-Yang, Kim Hyungtae, Church George M, Lee Charles, Kingsmore Stephen F and Seo Jeong-Sun.
    Literature
    MTHFR gene polymorphisms and response to chemotherapy in colorectal cancer: a meta-analysis.
    Pharmacogenomics. 2009. Zintzaras Elias, Ziogas Dimitrios C, Kitsios Georgios D, Papathanasiou Afroditi A, Lau Joseph and Raman Gowri.
    Literature
    Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial.
    Clinical cancer research : an official journal of the American Association for Cancer Research. 2009. Choi Ji-Yeob, Barlow William E, Albain Kathy S, Hong Chi-Chen, Blanco Javier G, Livingston Robert B, Davis Warren, Rae James M, Yeh I-Tien, Hutchins Laura F, Ravdin Peter M, Martino Silvana, Lyss Alan P, Osborne C Kent, Abeloff Martin D, Hayes Daniel F and Ambrosone Christine B.
    Literature
    Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.
    Pharmacogenomics. 2009. Amstutz Ursula, Farese Simone, Aebi Stefan and Largiadèr Carlo R.
    Literature
    GNAS1 T393C polymorphism is associated with histopathological response to neoadjuvant radiochemotherapy in esophageal cancer.
    The pharmacogenomics journal. 2009. Alakus H, Warnecke-Eberz U, Bollschweiler E, Mönig S P, Vallböhmer D, Brabender J, Drebber U, Baldus S E, Riemann K, Siffert W, Hölscher A H and Metzger R.
    Literature
    Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009. Goekkurt Eray, Al-Batran Salah-Eddin, Hartmann Jörg T, Mogck Ulrike, Schuch Gunter, Kramer Michael, Jaeger Elke, Bokemeyer Carsten, Ehninger Gerhard and Stoehlmacher Jan.
    Literature
    Pharmacogenetics and biomarkers in colorectal cancer.
    The pharmacogenomics journal. 2009. Strimpakos A S, Syrigos K N and Saif M W.
    Literature
    Association of thymidylate synthase variants with 5-fluorouracil cytotoxicity.
    Pharmacogenetics and genomics. 2009. Peters Eric J, Kraja Aldi T, Lin Shiow J, Yen-Revollo Jane L, Marsh Sharon, Province Michael A and McLeod Howard L.
    Literature
    C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation.
    European journal of cancer (Oxford, England : 1990). 2009. De Mattia Elena and Toffoli Giuseppe.
    Literature
    Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance.
    Molecular cancer therapeutics. 2009. Humeniuk Rita, Menon Lata G, Mishra Prasun J, Gorlick Richard, Sowers Rebecca, Rode Wojciech, Pizzorno Giuseppe, Cheng Yung-Chi, Kemeny Nancy, Bertino Joseph R and Banerjee Debabrata.
    Literature
    Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer.
    Cancer research. 2009. DeMichele Angela, Gray Robert, Horn Michelle, Chen Jinbo, Aplenc Richard, Vaughan William P and Tallman Martin S.
    Literature
    Interaction between two independent CNR1 variants increases risk for cocaine dependence in European Americans: a replication study in family-based sample and population-based sample.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2009. Zuo Lingjun, Kranzler Henry R, Luo Xingguang, Yang Bao-zhu, Weiss Roger, Brady Kathleen, Poling James, Farrer Lindsay and Gelernter Joel.
    Literature
    Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009. Cecchin Erika, Innocenti Federico, D'Andrea Mario, Corona Giuseppe, De Mattia Elena, Biason Paola, Buonadonna Angela and Toffoli Giuseppe.
    Literature
    Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer.
    British journal of cancer. 2009. Gusella M, Frigo A C, Bolzonella C, Marinelli R, Barile C, Bononi A, Crepaldi G, Menon D, Stievano L, Toso S, Pasini F, Ferrazzi E and Padrini R.
    Literature
    Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer.
    Cancer chemotherapy and pharmacology. 2009. Yuan Jianhui, Lv Hui, Peng Bo, Wang Chengkun, Yu Yanhui and He Zhimin.
    Literature
    Base excision by thymine DNA glycosylase mediates DNA-directed cytotoxicity of 5-fluorouracil.
    PLoS biology. 2009. Kunz Christophe, Focke Frauke, Saito Yusuke, Schuermann David, Lettieri Teresa, Selfridge Jim and Schär Primo.
    Literature
    Limits to thymidylate synthase and TP53 genes as predictive determinants for fluoropyrimidine sensitivity and further evidence for RNA-based toxicity as a major influence.
    Cancer research. 2009. Brody Jonathan R, Hucl Tomas, Costantino Christina L, Eshleman James R, Gallmeier Eike, Zhu Heng, van der Heijden Michiel S, Winter Jordan M, Wikiewicz Agnieszka K, Yeo Charles J and Kern Scott E.
    Literature
    Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.
    Gastroenterology. 2009. Farrell James J, Elsaleh Hany, Garcia Miguel, Lai Raymond, Ammar Ali, Regine William F, Abrams Ross, Benson A Bowen, Macdonald John, Cass Carol E, Dicker Adam P and Mackey John R.
    Literature
    ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells.
    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]. 2009. Hagmann Wolfgang, Jesnowski Ralf, Faissner Ralf, Guo Changqing and Löhr J Matthias.
    Literature
    High orotate phosphoribosyltransferase gene expression predicts complete response to chemoradiotherapy in patients with squamous cell carcinoma of the esophagus.
    Oncology. 2009. Kajiwara Takeshi, Nishina Tomohiro, Hyodo Ichinosuke, Moriwaki Toshikazu, Endo Shinji, Nasu Junichirou, Hori Shinichiro, Matsuura Bunzo, Hiasa Yoichi and Onji Morikazu.
    Literature
    Pharmacogenetics and pharmacogenomics of anticancer agents.
    CA: a cancer journal for clinicians. 2009. Huang R Stephanie and Ratain Mark J.
    Literature
    Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup?
    International journal of clinical oncology. 2008. Iacopetta Barry, Kawakami Kazuyuki and Watanabe Toshiaki.
    Literature
    Predictive Factors for Response and Toxicity in Chemotherapy: Pharmacogenomics.
    Seminars in colon & rectal surgery. 2008. Sanoff Hanna K and McLeod Howard L.
    Literature
    Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy.
    Journal of experimental & clinical cancer research : CR. 2008. Amstutz Ursula, Farese Simone, Aebi Stefan and Largiadèr Carlo R.
    Literature
    Prognostic role of p53 codon 72 polymorphism in gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy.
    Journal of cancer research and clinical oncology. 2008. Huang Zhao-Hui, Hua Dong, Li Li-Hua and Zhu Jing-De.
    Literature
    Transcription factor-binding sites in the thymidylate synthase gene: predictors of outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin?
    The pharmacogenomics journal. 2008. Paré L, Marcuello E, Altés A, del Rio E, Sedano L, Barnadas A and Baiget M.
    Literature
    Breast cancer resistance protein expression and 5-fluorouracil resistance.
    Biomedical and environmental sciences : BES. 2008. Yuan Jian-Hui, Cheng Jin-Quan, Jiang Long-Yuan, Ji Wei-Dong, Guo Liang-Feng, Liu Jian-Jun, Xu Xing-Yun, He Jing-Song, Wang Xian-Ming and Zhuang Zhi-Xiong.
    Literature
    Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival.
    International journal of cancer. 2008. Nordgard Silje H, Alnaes Grethe I G, Hihn Björn, Lingjaerde Ole Christian, Liestøl Knut, Tsalenko Anya, Sørlie Therese, Lønning Per Eystein, Børresen-Dale Anne-Lise and Kristensen Vessela N.
    Literature
    Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy.
    The pharmacogenomics journal. 2008. Ruzzo A, Graziano F, Loupakis F, Santini D, Catalano V, Bisonni R, Ficarelli R, Fontana A, Andreoni F, Falcone A, Canestrari E, Tonini G, Mari D, Lippe P, Pizzagalli F, Schiavon G, Alessandroni P, Giustini L, Maltese P, Testa E, Menichetti E T and Magnani M.
    Literature
    The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer.
    The pharmacogenomics journal. 2008. Capitain O, Boisdron-Celle M, Poirier A-L, Abadie-Lacourtoisie S, Morel A and Gamelin E.
    Literature
    Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition.
    Xenobiotica; the fate of foreign compounds in biological systems. 2008. Zhou S-F.
    Literature
    Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients.
    Journal of clinical pharmacy and therapeutics. 2008. He Y-F, Wei W, Zhang X, Li Y-H, Li S, Wang F-H, Lin X-B, Li Z-M, Zhang D-S, Huang H-Q, Hu B and Jiang W-Q.
    Literature
    Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14+1G > A mutation in the dihydropyrimidine dehydrogenase gene.
    Nucleosides, nucleotides & nucleic acids. 2008. van Kuilenburg A B P, Maring J G, Schalhorn A, Terborg C, Schmalenberg H, Behnke D, Schwabe W, Jabschinsky K and Hausler P.
    Literature
    CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.
    Cancer science. 2008. Fujita Ken-ichi, Yamamoto Wataru, Endo Shoji, Endo Hisashi, Nagashima Fumio, Ichikawa Wataru, Tanaka Ryuhei, Miya Toshimichi, Araki Kazuhiro, Kodama Keiji, Sunakawa Yu, Narabayashi Masaru, Miwa Keisuke, Ando Yuichi, Akiyama Yuko, Kawara Kaori, Kamataki Tetsuya and Sasaki Yasutsuna.
    Literature
    Low expression of gamma-glutamyl hydrolase mRNA in primary colorectal cancer with the CpG island methylator phenotype.
    British journal of cancer. 2008. Kawakami K, Ooyama A, Ruszkiewicz A, Jin M, Watanabe G, Moore J, Oka T, Iacopetta B and Minamoto T.
    Literature
    The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer.
    Clinical pharmacology and therapeutics. 2008. Kaida Y, Inui N, Suda T, Nakamura H, Watanabe H and Chida K.
    Literature
    Gilbert's Syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk.
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2008. Lankisch Tim O, Schulz Christoph, Zwingers Thomas, Erichsen Thomas J, Manns Michael P, Heinemann Volker and Strassburg Christian P.
    Literature
    ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study.
    BMC cancer. 2008. Huang Ming-Yii, Fang Wei-Yu, Lee Su-Chen, Cheng Tian-Lu, Wang Jaw-Yuan and Lin Shiu-Ru.
    Literature
    Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer.
    Pharmacogenetics and genomics. 2008. Lurje Georg, Zhang Wu, Yang Dongyun, Groshen Susan, Hendifar Andrew E, Husain Hatim, Nagashima Fumio, Chang Heung M, Fazzone William, Ladner Robert D, Pohl Alexandra, Ning Yan, Iqbal Syma, El-Khoueiry Anthony and Lenz Heinz-Josef.
    Literature
    Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?
    Clinical cancer research : an official journal of the American Association for Cancer Research. 2008. Yen-Revollo Jane L, Goldberg Richard M and McLeod Howard L.
    Literature
    Folylpolyglutamate synthase and gamma-glutamyl hydrolase regulate leucovorin-enhanced 5-fluorouracil anticancer activity.
    Biochemical and biophysical research communications. 2008. Sakamoto Etsuko, Tsukioka Sayaka, Oie Shinji, Kobunai Takashi, Tsujimoto Hiroaki, Sakamoto Kazuki, Okayama Yoshihiro, Sugimoto Yoshikazu, Oka Toshinori, Fukushima Masakazu and Oka Tatsuzo.
    Literature
    Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.
    Methods in molecular biology (Clifton, N.J.). 2008. Bosch Tessa M.
    Literature
    Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients.
    PloS one. 2008. Gross Eva, Busse Birgit, Riemenschneider Matthias, Neubauer Steffi, Seck Katharina, Klein Hanns-Georg, Kiechle Marion, Lordick Florian and Meindl Alfons.
    Literature
    Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism.
    Pharmacogenetics and genomics. 2007. Thomas Holly R, Ezzeldin Hany H, Guarcello Vincenzo, Mattison Lori K, Fridley Brooke L and Diasio Robert B.
    Literature
    Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
    The New England journal of medicine. 2007. Posner Marshall R, Hershock Diane M, Blajman Cesar R, Mickiewicz Elizabeth, Winquist Eric, Gorbounova Vera, Tjulandin Sergei, Shin Dong M, Cullen Kevin, Ervin Thomas J, Murphy Barbara A, Raez Luis E, Cohen Roger B, Spaulding Monica, Tishler Roy B, Roth Berta, Viroglio Rosana del Carmen, Venkatesan Varagur, Romanov Ilya, Agarwala Sanjiv, Harter K William, Dugan Matthew, Cmelak Anthony, Markoe Arnold M, Read Paul W, Steinbrenner Lynn, Colevas A Dimitrios, Norris Charles M, Haddad Robert I and TAX 324 Study Group.
    Literature
    Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
    The New England journal of medicine. 2007. Vermorken Jan B, Remenar Eva, van Herpen Carla, Gorlia Thierry, Mesia Ricard, Degardin Marian, Stewart John S, Jelic Svetislav, Betka Jan, Preiss Joachim H, van den Weyngaert Danielle, Awada Ahmad, Cupissol Didier, Kienzer Heinz R, Rey Augustin, Desaunois Isabelle, Bernier Jacques, Lefebvre Jean-Louis and EORTC 24971/TAX 323 Study Group.
    Literature
    DPYD*2A mutation: the most common mutation associated with DPD deficiency.
    Cancer chemotherapy and pharmacology. 2007. Saif M W, Ezzeldin Hany, Vance Katisha, Sellers Sandra and Diasio Robert B.
    Literature
    Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity.
    British journal of clinical pharmacology. 2007. Magné Nicolas, Etienne-Grimaldi Marie-Christine, Cals Laurent, Renée Nicole, Formento Jean-Louis, Francoual Mireille and Milano Gérard.
    Literature
    G>C SNP of thymidylate synthase with respect to colorectal cancer.
    Pharmacogenomics. 2007. Gusella Milena and Padrini Roberto.
    Literature
    Genome-wide screening of loci associated with drug resistance to 5-fluorouracil-based drugs.
    Cancer science. 2007. Ooyama Akio, Okayama Yoshihiro, Takechi Teiji, Sugimoto Yoshikazu, Oka Toshinori and Fukushima Masakazu.
    Literature
    Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007. Ruzzo Annamaria, Graziano Francesco, Loupakis Fotios, Rulli Eliana, Canestrari Emanuele, Santini Daniele, Catalano Vincenzo, Ficarelli Rita, Maltese Paolo, Bisonni Renato, Masi Gianluca, Schiavon Gaia, Giordani Paolo, Giustini Lucio, Falcone Alfredo, Tonini Giuseppe, Silva Rosarita, Mattioli Rodolfo, Floriani Irene and Magnani Mauro.
    Literature
    Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity.
    Therapeutic drug monitoring. 2007. Cho Hyun-Jung, Park Young Suk, Kang Won Ki, Kim Jong-Won and Lee Soo-Youn.
    Literature
    5-Fluorouracil incorporated into DNA is excised by the Smug1 DNA glycosylase to reduce drug cytotoxicity.
    Cancer research. 2007. An Qian, Robins Peter, Lindahl Tomas and Barnes Deborah E.
    Literature
    DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients.
    Medical oncology (Northwood, London, England). 2007. Zhang Hong, Li You-ming, Zhang Hao and Jin Xi.
    Literature
    Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences.
    Journal of human genetics. 2007. Maekawa Keiko, Saeki Mayumi, Saito Yoshiro, Ozawa Shogo, Kurose Kouichi, Kaniwa Nahoko, Kawamoto Manabu, Kamatani Naoyuki, Kato Ken, Hamaguchi Tetsuya, Yamada Yasuhide, Shirao Kuniaki, Shimada Yasuhiro, Muto Manabu, Doi Toshihiko, Ohtsu Atsushi, Yoshida Teruhiko, Matsumura Yasuhiro, Saijo Nagahiro and Sawada Jun-Ichi.
    Literature
    Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer.
    Anticancer research. 2007. Tsujie Masanori, Nakamori Shoji, Nakahira Shin, Takahashi Yuji, Hayashi Nobuyasu, Okami Jiro, Nagano Hiroaki, Dono Keizo, Umeshita Koji, Sakon Masato and Monden Morito.
    Literature
    Genomic signatures to guide the use of chemotherapeutics.
    Nature medicine. 2006. Potti Anil, Dressman Holly K, Bild Andrea, Riedel Richard F, Chan Gina, Sayer Robyn, Cragun Janiel, Cottrill Hope, Kelley Michael J, Petersen Rebecca, Harpole David, Marks Jeffrey, Berchuck Andrew, Ginsburg Geoffrey S, Febbo Phillip, Lancaster Johnathan and Nevins Joseph R.
    Literature
    A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Clinical pharmacology and therapeutics. 2006. Bocci Guido, Barbara Cecilia, Vannozzi Francesca, Di Paolo Antonello, Melosi Alessandro, Barsanti Gemma, Allegrini Giacomo, Falcone Alfredo, Del Tacca Mario and Danesi Romano.
    Literature
    FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006. Thussbas Christoph, Nahrig Jorg, Streit Sylvia, Bange Johannes, Kriner Monika, Kates Ronald, Ulm Kurt, Kiechle Marion, Hoefler Heinz, Ullrich Axel and Harbeck Nadia.
    Literature
    Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen.
    Clinical cancer research : an official journal of the American Association for Cancer Research. 2006. Ichikawa Wataru, Takahashi Takehiro, Suto Kenichi, Sasaki Yasutsuna and Hirayama Renzo.
    Literature
    The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006. Toffoli Giuseppe, Cecchin Erika, Corona Giuseppe, Russo Antonio, Buonadonna Angela, D'Andrea Mario, Pasetto Lara Maria, Pessa Sergio, Errante Domenico, De Pangher Vincenzo, Giusto Mauro, Medici Michele, Gaion Fernando, Sandri Paolo, Galligioni Enzo, Bonura Salvatore, Boccalon Massimo, Biason Paola and Frustaci Sergio.
    Literature
    Cancer and leukemia group B gastrointestinal cancer committee.
    Clinical cancer research : an official journal of the American Association for Cancer Research. 2006. Goldberg Richard M, Niedzwiecki Donna, Bertagnolli Monica, Blackstock A William, Tepper Joel E and Mayer Robert J.
    Literature
    Human methylenetetrahydrofolate reductase pharmacogenomics: gene resequencing and functional genomics.
    Pharmacogenetics and genomics. 2006. Martin Yvette N, Salavaggione Oreste E, Eckloff Bruce W, Wieben Eric D, Schaid Daniel J and Weinshilboum Richard M.
    Literature
    Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006. Dotor Emma, Cuatrecases Miriam, Martínez-Iniesta María, Navarro Matilde, Vilardell Felip, Guinó Elisabeth, Pareja Laura, Figueras Agnés, Molleví David G, Serrano Teresa, de Oca Javier, Peinado Miguel A, Moreno Víctor, Germà Josep Ramón, Capellá Gabriel and Villanueva Alberto.
    Literature
    Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients.
    Basic & clinical pharmacology & toxicology. 2006. Gunes Arzu, Coskun Ugur, Boruban Cem, Gunel Nazan, Babaoglu Melih O, Sencan Orhan, Bozkurt Atila, Rane Anders, Hassan Moustapha, Zengil Hakan and Yasar Umit.
    Literature
    Pharmacogenetics of extraordinary responses to 5-FU/cisplatin chemotherapy in advanced gastric cancer -- report of 2 cases.
    Onkologie. 2005. Wolschke Christine, Goekkurt Eray, Al-Batran Salah-Eddin, Hossfeld Dieter Kurt and Stoehlmacher Jan.
    Literature
    Polymorphic tandem repeat sequences of the thymidylate synthase gene correlates with cellular-based sensitivity to fluoropyrimidine antitumor agents.
    Cancer chemotherapy and pharmacology. 2005. Yawata Ayako, Kim Su-Ryang, Miyajima Atsuko, Kubo Takashi, Ishida Seiichi, Saito Yoshiro, Nakajima Yukiko, Katori Noriko, Matsumoto Yoshiaki, Fukuoka Masamichi, Ohno Yasuo, Ozawa Shogo and Sawada Jun-Ichi.
    Literature
    Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers.
    European journal of cancer (Oxford, England : 1990). 2005. Morganti Maria, Ciantelli Monica, Giglioni Beatrice, Putignano Anna L, Nobili Stefania, Papi Laura, Landini Ida, Napoli Cristina, Valanzano Rosa, Cianchi Fabio, Boddi Vieri, Tonelli Francesco, Cortesini Camillo, Mazzei Teresita, Genuardi Maurizio and Mini Enrico.
    Literature
    Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals.
    Clinical cancer research : an official journal of the American Association for Cancer Research. 2005. Seck Katharina, Riemer Silvia, Kates Ronald, Ullrich Tobias, Lutz Verena, Harbeck Nadia, Schmitt Manfred, Kiechle Marion, Diasio Robert and Gross Eva.
    Literature
    Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity.
    Drug metabolism and disposition: the biological fate of chemicals. 2005. Fukami Tatsuki, Nakajima Miki, Higashi Eriko, Yamanaka Hiroyuki, Sakai Haruko, McLeod Howard L and Yokoi Tsuyoshi.
    Literature
    Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts.
    Oncology reports. 2005. Takechi Teiji, Okabe Hiroyuki, Ikeda Kazumasa, Fujioka Akio, Nakagawa Fumio, Ohshimo Hideyuki, Kitazato Kenji and Fukushima Masakazu.
    Literature
    Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]).
    The Journal of pharmacy and pharmacology. 2005. Kobayashi Yasuna, Ohshiro Naomi, Sakai Ryoko, Ohbayashi Masayuki, Kohyama Noriko and Yamamoto Toshinori.
    Literature
    Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients.
    Pharmacogenetics. 2004. Etienne Marie-Christine, Formento Jean-Louis, Chazal Maurice, Francoual Mireille, Magné Nicolas, Formento Patricia, Bourgeon André, Seitz Jean-François, Delpero Jean-Robert, Letoublon Christian, Pezet Denis and Milano Gérard.
    Literature
    Multiple organ failure due to 5-fluorouracil chemotherapy in a patient with a rare dihydropyrimidine dehydrogenase gene variant.
    Onkologie. 2004. Lazar A, Mau-Holzmann U A, Kolb H, Reichenmiller H E, Riess O and Schömig E.
    Literature
    Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research. 2004. Noguchi Takuya, Tanimoto Keiji, Shimokuni Tatsushi, Ukon Kei, Tsujimoto Hiroaki, Fukushima Masakazu, Noguchi Tsuyoshi, Kawahara Katsunobu, Hiyama Keiko and Nishiyama Masahiko.
    Literature
    Identification of deletion-junction site of CYP2A6*4B allele lacking entire coding region of CYP2A6 in Japanese.
    Pharmacogenetics. 2004. Ariyoshi Noritaka, Sekine Hiromi, Nakayama Kazuo, Saito Katsuhiko, Miyamoto Atsushi and Kamataki Tetsuya.
    Literature
    Thymidylate synthase: a critical target in cancer therapy?
    Frontiers in bioscience : a journal and virtual library. 2004. Rustum Youcef M.
    Literature
    Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients.
    Clinical cancer research : an official journal of the American Association for Cancer Research. 2004. Rouits Elisabeth, Boisdron-Celle Michèle, Dumont Agnès, Guérin Olivier, Morel Alain and Gamelin Erick.
    Literature
    A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.
    British journal of cancer. 2004. Stoehlmacher J, Park D J, Zhang W, Yang D, Groshen S, Zahedy S and Lenz H-J.
    Literature
    Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population.
    Cancer chemotherapy and pharmacology. 2004. Hsiao Hui-Hua, Yang Ming-Yu, Chang Jan-Gowth, Liu Yi-Chang, Liu Ta-Chih, Chang Chao-Sung, Chen Tyen-Po and Lin Sheng-Fung.
    Literature
    Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate.
    Journal of the National Cancer Institute. 2004. Sohn Kyoung-Jin, Croxford Ruth, Yates Zoe, Lucock Mark and Kim Young-In.
    Literature
    Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity.
    British journal of cancer. 2004. Etienne M-C, Ilc K, Formento J-L, Laurent-Puig P, Formento P, Cheradame S, Fischel J-L and Milano G.
    Literature
    Cancer pharmacogenetics: polymorphisms, pathways and beyond.
    Nature reviews. Cancer. 2003. Ulrich Cornelia M, Robien Kim and McLeod Howard L.
    Literature
    Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity.
    Clinical cancer research : an official journal of the American Association for Cancer Research. 2003. van Kuilenburg André B P, Meinsma Rutger, Zonnenberg Bernard A, Zoetekouw Lida, Baas Frank, Matsuda Koichi, Tamaki Nanaya and van Gennip Albert H.
    Literature
    Ferredoxin reductase: pharmacogenomic assessment in colorectal cancer.
    Cancer research. 2003. Yu Jinsheng, Marsh Sharon, Ahluwalia Ranjeet and McLeod Howard L.
    Literature
    ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression.
    Cancer. 2003. Yang Wentao, Klos Kristine S, Zhou Xiaoyan, Yao Jun, Yang Ying, Smith Terry L, Shi Daren and Yu Dihua.
    Literature
    Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene.
    Cancer research. 2003. Kawakami Kazuyuki and Watanabe Go.
    Literature
    Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling.
    Cancer research. 2003. Maxwell Pamela J, Longley Daniel B, Latif Tariq, Boyer John, Allen Wendy, Lynch Maria, McDermott Ultan, Harkin D Paul, Allegra Carmen J and Johnston Patrick G.
    Literature
    Identification of a novel human uridine phosphorylase.
    Biochemical and biophysical research communications. 2003. Johansson Magnus.
    Literature
    5-fluorouracil: mechanisms of action and clinical strategies.
    Nature reviews. Cancer. 2003. Longley Daniel B, Harkin D Paul and Johnston Patrick G.
    Literature
    Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1.
    Pharmacogenetics. 2003. Osato Douglas H, Huang Conrad C, Kawamoto Michiko, Johns Susan J, Stryke Doug, Wang Joanne, Ferrin Thomas E, Herskowitz Ira and Giacomini Kathleen M.
    Literature
    Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research. 2003. Cohen Victor, Panet-Raymond Valerie, Sabbaghian Nelly, Morin Isabelle, Batist Gerald and Rozen Rima.
    Literature
    The contribution of cytochrome P450 to the metabolism of tegafur in human liver.
    Drug metabolism and pharmacokinetics. 2003. Kajita Jiro, Fuse Eiichi, Kuwabara Takashi and Kobayashi Hiroyuki.
    Literature
    High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity.
    Pharmacogenetics. 2002. Van Kuilenburg André B, Meinsma Rutger, Zoetekouw Lida and Van Gennip Albert H.
    Literature
    Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation.
    International journal of cancer. 2002. Van Kuilenburg André B P, Meinsma Rutger, Zoetekouw Lida and Van Gennip Albert H.
    Literature
    Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics.
    Pharmacogenomics. 2002. Mattison Lori K, Soong Richie and Diasio Robert B.
    Literature
    Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase.
    Biochimica et biophysica acta. 2002. Banerjee Debabrata, Mayer-Kuckuk Philipp, Capiaux Gina, Budak-Alpdogan Tulin, Gorlick Richard and Bertino Joseph R.
    Literature
    A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur.
    Pharmacogenetics. 2002. Daigo Satoshi, Takahashi Yoshiki, Fujieda Masaki, Ariyoshi Noritaka, Yamazaki Hiroshi, Koizumi Wasaburo, Tanabe Satoshi, Saigenji Katsunori, Nagayama Sekio, Ikeda Kazumasa, Nishioka Yasuhiko and Kamataki Tetsuya.
    Literature
    Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer.
    Journal of the National Cancer Institute. 2002. Stoehlmacher Jan, Park David J, Zhang Wu, Groshen Susan, Tsao-Wei Denice D, Yu Mimi C and Lenz Heinz-Josef.
    Literature
    Pharmacogenetics and folate metabolism -- a promising direction.
    Pharmacogenomics. 2002. Ulrich Cornelia M, Robien Kim and Sparks Rachel.
    Literature
    Uridine phosphorylase (-/-) murine embryonic stem cells clarify the key role of this enzyme in the regulation of the pyrimidine salvage pathway and in the activation of fluoropyrimidines.
    Cancer research. 2002. Cao Deliang, Russell Rosalind L, Zhang Dekai, Leffert Janine J and Pizzorno Giuseppe.
    Literature
    A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil.
    British journal of cancer. 2001. Iacopetta B, Grieu F, Joseph D and Elsaleh H.
    Literature
    Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.
    Clinical cancer research : an official journal of the American Association for Cancer Research. 2001. Raida M, Schwabe W, Häusler P, Van Kuilenburg A B, Van Gennip A H, Behnke D and Höffken K.
    Literature
    Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001. Villafranca E, Okruzhnov Y, Dominguez M A, García-Foncillas J, Azinovic I, Martínez E, Illarramendi J J, Arias F, Martínez Monge R, Salgado E, Angeletti S and Brugarolas A.
    Literature
    Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences.
    American journal of pharmacogenomics : genomics-related research in drug development and clinical practice. 2001. Schwahn B and Rozen R.
    Literature
    Therapeutic drug monitoring of cytotoxic drugs.
    British journal of clinical pharmacology. 2001. Lennard L.
    Literature
    Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy.
    The pharmacogenomics journal. 2001. Pullarkat S T, Stoehlmacher J, Ghaderi V, Xiong Y P, Ingles S A, Sherrod A, Warren R, Tsao-Wei D, Groshen S and Lenz H J.
    Literature
    Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.
    Clinical cancer research : an official journal of the American Association for Cancer Research. 2000. van Kuilenburg A B, Haasjes J, Richel D J, Zoetekouw L, Van Lenthe H, De Abreu R A, Maring J G, Vreken P and van Gennip A H.
    Literature
    Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes.
    Drug metabolism and disposition: the biological fate of chemicals. 2000. Komatsu T, Yamazaki H, Shimada N, Nakajima M and Yokoi T.
    Literature
    Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro.
    Clinical cancer research : an official journal of the American Association for Cancer Research. 2000. Ikeda K, Yoshisue K, Matsushima E, Nagayama S, Kobayashi K, Tyson C A, Chiba K and Kawaguchi Y.
    Literature
    Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research. 2000. van Triest B, Pinedo H M, Blaauwgeers J L, van Diest P J, Schoenmakers P S, Voorn D A, Smid K, Hoekman K, Hoitsma H F and Peters G J.
    Literature
    Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency.
    Clinical chemistry. 2000. Van Kuilenburg A B, Van Lenthe H, Tromp A, Veltman P C and Van Gennip A H.
    Literature
    MTHFR (C677T) polymorphisms and stage III colon cancer: response to therapy.
    Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology. 1999. Wisotzkey J D, Toman J, Bell T, Monk J S and Jones D.
    Literature
    Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity.
    British journal of cancer. 1999. Milano G, Etienne M C, Pierrefite V, Barberi-Heyob M, Deporte-Fety R and Renée N.
    Literature
    Therapeutic drug monitoring of antimetabolic cytotoxic drugs.
    British journal of clinical pharmacology. 1999. Lennard L.
    Literature
    Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency.
    Human genetics. 1999. Van Kuilenburg A B, Vreken P, Abeling N G, Bakker H D, Meinsma R, Van Lenthe H, De Abreu R A, Smeitink J A, Kayserili H, Apak M Y, Christensen E, Holopainen I, Pulkki K, Riva D, Botteon G, Holme E, Tulinius M, Kleijer W J, Beemer F A, Duran M, Niezen-Koning K E, Smit G P, Jakobs C, Smit L M and Van Gennip A H.
    Literature
    Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers.
    Anticancer research. 1999. Kawakami K, Omura K, Kanehira E and Watanabe Y.
    Literature
    Characterization of the human dihydropyrimidine dehydrogenase gene.
    Genomics. 1998. Wei X, Elizondo G, Sapone A, McLeod H L, Raunio H, Fernandez-Salguero P and Gonzalez F J.
    Literature
    Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects.
    British journal of clinical pharmacology. 1998. Ridge S A, Sludden J, Brown O, Robertson L, Wei X, Sapone A, Fernandez-Salguero P M, Gonzalez F J, Vreken P, van Kuilenburg A B, van Gennip A H and McLeod H L.
    Literature
    Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.
    European journal of cancer (Oxford, England : 1990). 1998. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I and Ishitsuka H.
    Literature
    Preclinical evaluation of CPT-11 and its active metabolite SN-38.
    Seminars in oncology. 1996. Lavelle F, Bissery M C, André S, Roquet F and Riou J F.
    Literature
    Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency.
    Trends in pharmacological sciences. 1995. Gonzalez F J and Fernandez-Salguero P.
    Literature
    Population study of dihydropyrimidine dehydrogenase in cancer patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1994. Etienne M C, Lagrange J L, Dassonville O, Fleming R, Thyss A, Renée N, Schneider M, Demard F and Milano G.
    Literature
    Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity.
    The Journal of clinical investigation. 1988. Diasio R B, Beavers T L and Carpenter J T.
    Literature
    CPIC® Guideline for Fluoropyrimidines and DPYD – CPIC
    PGx Paper Type: Implementation
    Literature
    DailyMed - FLUOROURACIL injection, solution
    Literature
    Drugs@HCSC: Drug Product fluorouracil cream (EFUDEX)
    Literature
    Drugs@HCSC: Drug Product fluorouracil injection
    Literature
    Dutch Pharmacogenetics Working Group Guidelines August 2019
    Literature
    Dutch Pharmacogenetics Working Group Guidelines November 2018
    Literature
    Swissmedic label for fluorouracil (Efudix)
    Literature
    Swissmedic label for fluorouracil (Fluorouracil Labatec)